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Background: Convulsive status epilepticus is the most common neurological emergency in children.
Its management is important to avoid or minimise neurological morbidity and death. The current
first-choice second-line drug is phenytoin (Epanutin, Pfizer Inc., New York, NY, USA), for which there is
no robust scientific evidence.
Objective: To determine whether phenytoin or levetiracetam (Keppra, UCB Pharma, Brussels, Belgium)
is the more clinically effective intravenous second-line treatment of paediatric convulsive status
epilepticus and to help better inform its management.
Design: A multicentre parallel-group randomised open-label superiority trial with a nested mixed-method
study to assess recruitment and research without prior consent.
Setting: Participants were recruited from 30 paediatric emergency departments in the UK.
Participants: Participants aged 6 months to 17 years 11 months, who were presenting with convulsive
status epilepticus and were failing to respond to first-line treatment.
Interventions: Intravenous levetiracetam (40 mg/kg) or intravenous phenytoin (20 mg/kg).
Main outcome measures: Primary outcome – time from randomisation to cessation of all visible
signs of convulsive status epilepticus. Secondary outcomes – further anticonvulsants to manage the
convulsive status epilepticus after the initial agent, the need for rapid sequence induction owing to
ongoing convulsive status epilepticus, admission to critical care and serious adverse reactions.
Results: Between 17 July 2015 and 7 April 2018, 286 participants were randomised, treated and
consented. A total of 152 participants were allocated to receive levetiracetam and 134 participants to
receive phenytoin. Convulsive status epilepticus was terminated in 106 (70%) participants who were
allocated to levetiracetam and 86 (64%) participants who were allocated to phenytoin. Median time from
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randomisation to convulsive status epilepticus cessation was 35 (interquartile range 20–not assessable)
minutes in the levetiracetam group and 45 (interquartile range 24–not assessable) minutes in the
phenytoin group (hazard ratio 1.20, 95% confidence interval 0.91 to 1.60; p = 0.2). Results were robust
to prespecified sensitivity analyses, including time from treatment commencement to convulsive status
epilepticus termination and competing risks. One phenytoin-treated participant experienced serious
adverse reactions.
Limitations: First, this was an open-label trial. A blinded design was considered too complex, in part
because of the markedly different infusion rates of the two drugs. Second, there was subjectivity in the
assessment of ‘cessation of all signs of continuous, rhythmic clonic activity’ as the primary outcome,
rather than fixed time points to assess convulsive status epilepticus termination. However, site training
included simulated demonstration of seizure cessation. Third, the time point of randomisation resulted
in convulsive status epilepticus termination prior to administration of trial treatment in some cases.
This affected both treatment arms equally and had been prespecified at the design stage. Last, safety
measures were a secondary outcome, but the trial was not powered to demonstrate difference in
serious adverse reactions between treatment groups.
Conclusions: Levetiracetam was not statistically superior to phenytoin in convulsive status epilepticus
termination rate, time taken to terminate convulsive status epilepticus or frequency of serious adverse
reactions. The results suggest that it may be an alternative to phenytoin in the second-line management
of paediatric convulsive status epilepticus. Simple trial design, bespoke site training and effective
leadership were found to facilitate practitioner commitment to the trial and its success. We provide a
framework to optimise recruitment discussions in paediatric emergency medicine trials.
Future work: Future work should include a meta-analysis of published studies and the possible
sequential use of levetiracetam and phenytoin or sodium valproate in the second-line treatment of
paediatric convulsive status epilepticus.
Trial registration: Current Controlled Trials ISRCTN22567894 and European Clinical Trials Database
EudraCT number 2014-002188-13.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 58. See the NIHR Journals Library website for further project information.
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Plain English summary
Most epileptic tonic–clonic seizures, also called convulsions, last for < 4 minutes and stopspontaneously. A convulsion that lasts for > 5 minutes is called convulsive status epilepticus.
This may cause neurological abnormalities or, rarely, death.
There is good scientific evidence for the best first-line medicine, called a benzodiazepine, to stop
convulsive status epilepticus. When a benzodiazepine has not stopped status, a second-line medicine
is given. The usual second-line medicine, which has been used for > 50 years, is phenytoin (Epanutin,
Pfizer Inc., New York, NY, USA). However, it stops status in only half of children. It must be given
slowly because it can cause unpleasant and potentially serious side effects. A new medicine called
levetiracetam (Keppra, UCB Pharma, Brussels, Belgium) may be more effective. It seems to have less
serious side effects than phenytoin. However, there is no good scientific evidence as to whether
phenytoin or levetiracetam is better. A randomised controlled trial is the best scientific way to decide
which of these two medicines is better.
The Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE)
trial was a randomised controlled trial that compared levetiracetam with phenytoin. A total of
152 children were randomised to receive levetiracetam and a total of 134 children were randomised
to receive phenytoin. Research without prior consent was shown to be acceptable to parents, doctors
and nurses. Parents’ consent to use their child’s data and continue in the trial was provided after the
emergency situation was resolved.
Convulsive status epilepticus stopped in 70.4% of the levetiracetam-treated children and in 64% of the
phenytoin-treated children.
The median time to status stopping was 35 minutes in the levetiracetam-treated children and 45 minutes
in the phenytoin-treated children.
Only one participant on phenytoin (vs. none on levetiracetam) experienced serious side effects that
were thought to be caused by their treatment.
None of the results showed any statistically significant or meaningful difference between levetiracetam
and phenytoin. However, the results suggest that levetiracetam might be an alternative choice to phenytoin.
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Scientific summary
Background
Convulsive status epilepticus is the most common life-threatening neurological emergency in childhood,
with a mortality rate of 1–5%. These children are also at risk of significant morbidity, with acute and
chronic impacts on the family and health and social care systems. Intravenous phenytoin (Epanutin,
Pfizer Inc., New York, NY, USA) [fosphenytoin (Pro-Epanutin, Pfizer Inc.) in the USA] is the current
recommended first-choice second-line treatment in children aged ≥ 6 months. However, there is no
good randomised controlled trial evidence for its use and it is associated with significant and potentially
serious side effects. Emerging evidence suggests that intravenous levetiracetam (Keppra, UCB Pharma,
Brussels, Belgium) may be clinically effective as a second-line agent for convulsive status epilepticus,
with fewer reported adverse effects. This trial aimed to determine whether intravenous phenytoin or
intravenous levetiracetam is more effective and safer in treating childhood convulsive status epilepticus.
Aims and objectives
The study objectives were to determine:
1. whether intravenous phenytoin or intravenous levetiracetam is the more efficacious second-line
anticonvulsant for the emergency management of convulsive status epilepticus in children
2. whether or not intravenous levetiracetam is associated with fewer adverse reactions or events than
intravenous phenytoin
3. the potential barriers and solutions to recruitment and consent in the EcLiPSE trial to inform future
trials with regard to recruiter training and trial conduct in this clinical setting (i.e. a nested
consent study).
Methods
Study design
This was a Phase IV, multicentre, parallel-group, randomised controlled, open-label superiority trial that
took place in a paediatric emergency department. Following first-line treatment for convulsive status
epilepticus, children with a continuing convulsive seizure were randomised to receive either phenytoin
(20 mg/kg, with a maximum of 2 g) or levetiracetam (40 mg/kg, with a maximum of 2.5 g) intravenously.
The primary outcome was time from randomisation to cessation of all visible signs of convulsive status
epilepticus. All ‘visible signs of convulsive activity’ was defined by cessation of all continuous rhythmic
motor activity, as determined by the treating clinician. Secondary outcome measures were the need
for further anticonvulsants to manage the convulsive status epilepticus, rapid sequence induction for
ongoing convulsive status epilepticus, admission to critical care (either a high-dependency unit or a
paediatric intensive care unit) and serious adverse reactions. Patients were randomised and treated
without prior consent, with consent sought after the emergency situation.
The consent study methods included questionnaires and interviews with parents of randomised
children, interviews and focus groups with EcLiPSE trial practitioners and audio-recorded
trial discussions.
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Eligibility criteria
Inclusion criteria
l Males and females aged 6 months to 17 years and 11 months (inclusive).
l The presenting seizure was a generalised tonic–clonic, generalised clonic or focal clonic convulsive
seizure that required second-line treatment to terminate the seizure (i.e. convulsive
status epilepticus).
l First-line treatment administered in accordance with advanced paediatric life support guidelines or
the child’s personalised rescue care plan to try to terminate the presenting seizure.
Eligibility notes
Patients with the following features were eligible for inclusion in the trial, assuming that all other
inclusion and exclusion criteria were met.
l Patients administered more than two doses of benzodiazepines, which is above the recommended
dose in advanced paediatric life support guidelines.
l Patients whose personalised rescue care plan included rectal paraldehyde as the first-line treatment.
l Patients receiving oral phenytoin or levetiracetam as part of their regular maintenance oral
antiepileptic drug regime.
Exclusion criteria
l Absence, myoclonic or non-convulsive status epilepticus, or infantile spasms.
l Patients with a known or suspected pregnancy.
l Patients with known contraindication or allergy to levetiracetam or phenytoin. This included when
the child’s personalised rescue care plan stated that the child never responded to, or had previously
experienced a severe adverse reaction to, phenytoin, levetiracetam or both.
l Patients with known renal failure (patients on peritoneal or haemodialysis, or with renal function
that is < 50% expected for age).
l Previous administration of a second-line antiepileptic drug prior to arrival in the
emergency department.
l Patients known to have previously been treated as part of the EcLiPSE trial.
Parents/legal representatives who did and did not consent to their child’s participation in the trial and
all practitioners involved in screening, recruiting, randomising and consenting parents/legal representatives
were eligible to take part in the consent study.
Recruitment
Patients were assessed by clinical staff to determine if they were eligible for the trial.
No attempt was made to obtain fully informed consent for the trial from the participant/parent/legal
representative prior to randomisation or treatment. Consent was ideally sought within 24 hours
after randomisation and patient follow-up was completed, regardless of whether or not a second-line
treatment was administered. If consent was refused, all data and samples collected for the trial
were destroyed.
Consent was sought from parents/legal representatives to participate in each element of the consent
study as part of the EcLiPSE trial consent process. E-mail invitations were sent to practitioners, inviting
them to participate in a focus group or an interview.
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Randomisation
Eligible children were randomised following completion of first-line therapy if the convulsive status
epilepticus continued. This enabled the preparation and administration of the allocated treatment in
a time frame consistent with advanced paediatric life support guidance for the management of
convulsive status epilepticus.
If the convulsive status epilepticus terminated prior to administration of the allocated treatment but
then restarted before the patient left the emergency department, the patient would then be given
the allocated treatment. Randomised participants who did not receive a second-line treatment in the
emergency department were not included in the primary or secondary analyses.
Participants were randomised to levetiracetam or phenytoin in a ratio of 1 : 1. The randomisation code
list was generated by an independent statistician. Randomisation packs were numbered sequentially,
and opaque, tamper-proof envelopes were opened in ascending order. Checks were performed
periodically to ensure that the correct number of randomisation packs were present and intact, and
that the sequential numbering system was maintained. The envelopes contained the first case report
form, which was completed in the emergency department during the convulsive status epilepticus
episode. Data collected included time of drug administration, convulsive status epilepticus cessation,
additional therapy required, adverse events and whether or not the child was discharged from the
emergency department or where they were admitted to.
Outcome measures
Primary outcome
The primary outcome was time from randomisation to cessation of all visible signs of convulsive status
epilepticus activity, defined as cessation of all rhythmic convulsive activity.
Secondary outcomes
The secondary outcomes were as follows.
1. Need for further anticonvulsants to manage seizures after randomised treatment.
2. Need for rapid sequence induction because of ongoing convulsive status epilepticus.
3. Need for admission to a critical care unit (i.e. high-dependency unit or paediatric intensive
care unit).
4. Serious adverse reactions, which included death, Stevens–Johnson syndrome, rash, airway
complications, cardiovascular instability, extravasation injury and extreme agitation.
Sample size
The sample size was based on published seizure cessation rates for phenytoin (50–60%) and
levetiracetam (76–100%). A sample size of 140 participants in each group with a total of 183 events of
convulsive status epilepticus cessation was required to achieve 80% power to detect an increase in
convulsive status epilepticus cessation rates from 60% to 75%, with a 5% significance level two-sided
log-rank test for equality of survival curves.
An adjustment for 10% loss to follow-up increased sample size requirements to a total of 308 randomised
participants. However, as this did not occur, the final sample size was reduced to 286 participants, as
approved by the trial oversight committees.
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Statistical methods
The modified intention-to-treat population excluded patients who did not require second-line
treatment and patients who did not give consent. It included all randomised, consented patients who
received a second-line treatment in the group to which they were randomly allocated.
The safety population included all randomised, consented and treated patients in the group of the
treatment that the patient actually received.
The primary analysis was by ‘intention to treat’. A 5% level of statistical significance was used
throughout and all results are presented with 95% confidence intervals. The primary outcome is
a time-to-event outcome and was analysed using the log-rank test and Kaplan–Meier curves.
Dichotomous outcomes were analysed using the chi-square test and presented with relative risks.
Adjusted analyses were conducted using Cox proportional hazards models or logistic regression, as
appropriate. Variables included in the models were determined from known prognostic factors. Serious
adverse reactions are presented using descriptive statistics. Reasons for missing data, and rates and
reasons for not obtaining deferred consent, were collected.
Consent study data analysis used descriptive statistics and chi-square test for trend. Qualitative data
were analysed thematically. Data from study methods were analysed separately and then synthesised
through constant comparative analysis.
Results
A total of 1432 patients were screened for eligibility. Four hundred and four participants were randomised
(n= 212 levetiracetam, n= 192 phenytoin) and 311 participants (n= 161 levetiracetam, n= 150 phenytoin)
required a second-line treatment. Valid consent was obtained for 286 participants (n= 152 levetiracetam,
n= 134 phenytoin) who formed the modified intention-to-treat population. The safety population
comprised 149 patients treated with levetiracetam and 137 patients treated with phenytoin.
Males constituted 49% (75/152) of the levetiracetam-treated group and 54% (72/134) of the
phenytoin-treated group.
The median age was 2.7 (interquartile range 1.3–5.9) years in the levetiracetam-treated group and 2.7
(interquartile range 1.6–5.6) years in the phenytoin-treated group. Children aged < 2 years comprised
43% (65/152) and 40% (53/134) of the levetiracetam- and phenytoin-treated groups, respectively.
The presenting episode of convulsive status epilepticus was the first seizure in 45% (69/152) and 37%
(49/134) of the levetiracetam- and phenytoin-treated groups, respectively.
Primary outcome
The episode of convulsive status epilepticus terminated in 106 (70%) and 86 (64%) participants of the
levetiracetam- and phenytoin-treated groups, respectively. The log-rank test for time to seizure cessation
was not statistically significant (p = 0.20), with the median time to seizure cessation (from randomisation)
being 35 (interquartile range 20–not assessable) minutes and 45 (interquartile range 24–not assessable)
minutes in the levetiracetam- and phenytoin-treated groups, respectively [unadjusted hazard ratio 1.20,
95% confidence interval 0.91 to 1.60, p = 0.20; adjusted (sex, weight and first seizure) hazard ratio 1.23,
95% confidence interval 0.92 to 1.63; p = 0.16].
Sensitivity analyses undertaken on the primary outcome confirmed the robustness of the results.
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Secondary outcomes
Fifty-seven (38%) and 50 (37%) participants in the levetiracetam- and phenytoin-treated groups,
respectively, received additional anticonvulsants (relative risk 1.01, 95% confidence interval 0.74 to
1.36; p = 0.97). Results were similar when restricted to the further management for the presenting
episode of convulsive status epilepticus.
Forty-four (29.5%) participants in the levetiracetam group and 47 (35%) participants in the phenytoin
group received rapid sequence induction because of ongoing convulsive status epilepticus (relative risk
0.83, 95% confidence interval 0.59 to 1.16; p = 0.27).
Ninety-seven (64%) participants in the levetiracetam group and 72 (54%) participants in the phenytoin
group were admitted to critical care (relative risk 1.19, 95% confidence interval 0.97 to 1.45; p = 0.08).
Safety data were analysed by the treatment received. One hundred and thirty-two participants
received levetiracetam only and 130 participants received phenytoin only. The remaining 24 participants
received both treatments sequentially (i.e. 17 participants received levetiracetam followed by phenytoin
and seven participants received phenytoin followed by levetiracetam).
Five serious adverse events were reported. Three serious adverse events occurred in two participants
receiving phenytoin, one serious adverse event occurred in a participant receiving levetiracetam and
one serious adverse event occurred in a participant who received both interventions. Four serious
adverse events were resolved and the remaining serious adverse event occurred in a participant who
died. The cause of death was catastrophic cerebral oedema and encephalitis that was unrelated to
either treatment. This participant received levetiracetam followed by phenytoin. Two serious adverse
events were assessed as having a causal relationship with treatment (one was classed as a serious
adverse reaction and the other as a suspected unexpected serious adverse reaction). The serious
adverse reaction was hypotension considered to be immediately life-threatening and the suspected
unexpected serious adverse reaction was increased focal seizures and decreased consciousness
considered to be medically significant. Both occurred in the same participant who was allocated and
given phenytoin. The remaining serious adverse event occurred in a levetiracetam-treated participant
who experienced a cardiorespiratory arrest owing to an obstructed endotracheal tube, which was
considered unrelated to treatment.
In the consent study, 143 parents of randomised children (93 mothers, 39 fathers and 11 parents with
missing information) completed a questionnaire and 30 (25 mothers and five fathers) were interviewed.
Ten practitioners (four medical and six nursing) were interviewed, 36 (16 medical and 20 nursing)
participated in one of six focus groups and 76 recorded trial discussions that were analysed.
Consent study findings showed how interactive site training, developed using pre-trial research and
research without prior consent guidance, may significantly alleviate practitioner concerns about
recruitment and consent in a challenging paediatric emergency medicine trial. Parental understanding
of the EcLiPSE trial was enhanced when practitioners clearly described the trial aims, provided reasons
for research without prior consent, explained the uncertainty about which intervention was best,
provided a balanced description of both interventions, explained the randomisation process and
provided an opportunity for questions. Multiple factors, including trial design, organisation and
leadership, were found to both challenge and contribute to trial recruitment and conduct. The nested
consent study provides valuable insight from parents and practitioners to inform the design and
conduct of future trials in this setting, including a bespoke model to optimise discussions on
recruitment into paediatric emergency medicine trials.
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Conclusions
The two treatment groups were well balanced in terms of demographic profiles.
None of the primary and secondary outcome data demonstrated a statistically significant difference
between levetiracetam and phenytoin. However, the direction of the results favoured levetiracetam in
the primary outcome and most secondary outcomes (i.e. seizure cessation, time to seizure cessation,
need for rapid sequence induction and serious adverse reactions). The findings favoured phenytoin in
one secondary outcome (i.e. the need to be admitted to critical care).
The study demonstrated the acceptability of research without prior consent in the paediatric
emergency setting, and how training and recruitment experience addressed clinicians’ concerns about
research without prior consent.
Recommendations for future research
A meta-analysis of all randomised controlled trial data on the use of levetiracetam as a second-line
drug should be undertaken. This is one of the priorities of the EcLiPSE trial team. The role of sodium
valproate and the sequential use of two anticonvulsants, specifically levetiracetam followed by
phenytoin or levetiracetam followed by sodium valproate, could also be investigated. This would
determine whether or not the use of two drugs reduces the need for third-line treatment with an
anaesthetic, but without significantly prolonging convulsive status epilepticus.
Trial registration
This trial is registered as ISRCTN22567894 and European Clinical Trials Database EudraCT number
2014-002188-13.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 58.
See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
Parts of this chapter have been reused from Lyttle et al.1 This is an Open Access article distributedin accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license,
which permits others to copy and redistribute the material in any medium or format, provided the
original work is properly cited. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
Parts of this chapter have been reused from Lyttle et al.2 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original
work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor
additions and formatting changes to the original text.
In addition, the exclusion criteria have been reused from the study ISRCTN registry.3 This article is
available under the terms of the Creative Commons Attribution License http://creativecommons.org/
licenses/by/4.0/.
Scientific background
Convulsive status epilepticus (CSE) is the most common life-threatening neurological emergency in
children, with an incidence of 20 per 100,000 children per year.4,5 It is the second most common reason
for unplanned admission to paediatric intensive care units (PICUs) in the UK, accounting for 5.6% of
all PICU admissions.6 Mortality is low, but morbidity, including neurodisability, learning difficulties and
de novo and drug-resistant epilepsy, may be as high as 22%.7–10 Predictably, these may result in major
long-term demands on acute and chronic health and social care resources.4 The longer the duration of
CSE, the more difficult it is to terminate and the greater the morbidity risk.4,9,10
The current UK emergency care pathway for the management of childhood CSE is the stepwise
algorithm that is advocated in advanced paediatric life support (APLS) guidance.11 First-line treatment
is two doses of a benzodiazepine given 10 minutes apart. A second-line anticonvulsant is administered
if the child continues to fit 10 minutes after the second dose of benzodiazepine. APLS guidance
recommends phenytoin (Epanutin, Pfizer Inc., New York, NY, USA) as the first-choice second-line
anticonvulsant. Phenobarbital (AAH Pharmaceuticals, Coventry, UK) is recommended if the child is
allergic to phenytoin, has previously not responded to it or has experienced a serious adverse event
(SAE). Failure to stop CSE necessitates rapid sequence induction (RSI), intubation and admission to
PICU, with consequent potential for iatrogenic consequences, including pneumonia, hospital-acquired
infections and prolonged admission.
There is reasonable randomised controlled trial (RCT) evidence to support the use of benzodiazepines
as first-line anticonvulsants,12 but there is a dearth of evidence for second-line drug treatment and no
high-quality RCT evidence to support any second-line treatment.13 There is an absence of randomised
evidence to support the use of phenytoin as the second-line anticonvulsant, despite its use as a
standard intravenous (i.v.) anticonvulsant for the treatment of CSE since the 1940s. A retrospective
case note review, in which 87% (331/381) of children administered a second-line anticonvulsant
received phenytoin, reported seizure cessation in 190 cases (50%).14 There is considerably more
literature on phenytoin’s potential adverse effects, including potentially fatal cardiac arrhythmias
and Stevens–Johnson syndrome (Tables 1 and 2).15–18 The risk of a cardiac arrhythmia is related to
the rate of infusion and, therefore, phenytoin must be infused over a period of at least 20 minutes.18
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TABLE 1 Reasons for ineligibility
Eligibility
criteria Reason for ineligibilitya
Number of
patients
Inclusion
1 Outside age range 23
2 Patient does not present with generalised tonic–clonic, generalised clonic or focal clonic
status epilepticus that requires second-line treatment to terminate the seizureb
656
3 First-line treatment not administered in accordance with APLS guidelines or personalised
rescue care plan to try and terminate the seizure
133
Exclusion
1 Absence, myoclonic or non-CSE, or infantile spasms 100
2 Known or suspected pregnancy 0
3 Contraindication or allergy to either trial treatment 45
4 Known renal failure (i.e. patients on peritoneal or haemodialysis, or with renal function that
is < 50% expected for age)
3
5 Previous administration of a second-line antiepileptic drug prior to arrival in the ED 7
6 Had previously entered the EcLiPSE trial 38
EcLiPSE, Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children; ED, emergency department.
a Not mutually exclusive.
b See Table 2.
TABLE 2 Eligibility of seizure type
Data recorded Assumption
Number of
patients
Patient recorded as ‘no’ to inclusion criterion 2
and ‘yes’ to exclusion criterion 1, but their seizure
continued after benzodiazepines
Patient had incorrect seizure type 21
Patient recorded as ‘no’ to inclusion criterion 2
and ‘no’ to exclusion criterion 1 and their seizure
stopped after benzodiazepines
No second-line treatment was required (seizure
stopped), but patient had correct seizure type
533
Patient recorded as ‘no’ to inclusion criterion 2
and ‘yes’ to exclusion criterion 1 and their seizure
stopped after benzodiazepines
Patient had incorrect seizure type and no
second-line treatment was required
57
Missing response for exclusion criterion 1 No assumptions made: data confirmed as
unobtainable
3
Patient recorded ‘no’ to inclusion criterion 2 and
‘no’ to exclusion criterion 1 and their seizure
continued after benzodiazepines
No assumptions made: data suggested correct
seizure type and seizure continuing
11
Patient has no benzodiazepines recorded No assumptions made 19
Patient has missing benzodiazepine administration
outcome
No assumptions made: data confirmed
as unobtainable
3
Patient has other outcome recorded for
benzodiazepines
No assumptions made 9
Total 656
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
Levetiracetam (Keppra, UCB Pharma, Brussels, Belgium) is a broad-spectrum anticonvulsant that
effectively treats focal and generalised tonic–clonic and myoclonic seizures. A growing body of
evidence, predominantly, but not exclusively, anecdotal, suggests that i.v. levetiracetam is safe and
effective in the treatment of acute repetitive seizures and both CSE and non-CSE, with reported
seizure cessation rates between 76% and 100%.19–27 There is limited evidence that i.v. levetiracetam
may also be as effective as i.v. lorazepam (Ativan, Pfizer Inc.), which is the current first-choice first-line
anticonvulsant in the treatment of CSE. Levetiracetam and lorazepam administered intravenously to
79 patients (the majority of whom were adults) were equally effective in terminating CSE {levetiracetam
terminated CSE in 76.3% of patients and lorazepam in 75.6% of patients [relative risk 0.97, 95%
confidence interval (CI) 0.44 to 2.13]}.28 A systematic review of levetiracetam published in 201229
indicated that efficacy ranged from 44% to 94%, with reported higher rates in retrospective studies.
Two RCTs, published in 2015, involving predominantly adults, directly compared i.v. levetiracetam with
either i.v. phenytoin30 or i.v. phenytoin plus i.v. sodium valproate (Epilim, Sanofi, Paris, France)31 and
showed no difference between the comparators. Chakravarthi et al.30 reported on 44 patients who
presented with ‘consecutive status’ and were randomised to treatment with phenytoin (20 mg/kg) or
levetiracetam (20 mg/kg). Both drugs showed a similar efficacy in status termination within 30 minutes
of commencement of drug infusion. Phenytoin achieved control in 15 out of 22 (68.2%) patients and
levetiracetam in 13 out of 22 (59.1%) patients (p = 0.53).30 In the study reported by Mundlamuri et al.,31
the presenting seizure was controlled with lorazepam plus phenytoin infusion in 34 out of 50 (68%)
patients, lorazepam plus valproate infusion in 34 out of 50 (68%) patients and with lorazepam plus
levetiracetam infusion in 39 out of 50 (78%) patients. There was no statistically significant difference
between the subgroups (p = 0.44).31 Reported i.v. levetiracetam doses range from 20 to 60 mg/kg.
Chakravarthi et al.30 and Mundlamuri et al.31 used doses of 20 mg/kg and 25 mg/kg, respectively.
Adverse reactions (ARs) with levetiracetam seem to be infrequent and mild, even at high doses.
These include dizziness, somnolence, headache and transient agitation, but there have been no
reports of cardiac arrhythmias, hypotension, tissue extravasation reactions, Stevens–Johnson
syndrome or hepatotoxicity.32–34 Levetiracetam can be infused over 5–10 minutes, which suggests
that, theoretically, CSE may be terminated more rapidly than with phenytoin. Consequently, a
reasonable hypothesis is that levetiracetam may be more effective and safer than i.v. phenytoin
in terminating CSE.13,35,36
Convulsive status epilepticus management was identified as a key priority area for research by a
number of sources, including the Paediatric Emergency Research in the UK and Ireland (PERUKI)37,38 in
its inaugural prioritisation exercise,38 and the National Institute for Health and Care Excellence in its
update of national epilepsy guidelines published in January 2012.39 A high-quality RCT is, therefore,
essential to determine whether phenytoin or levetiracetam is the better drug in managing CSE, as
highlighted in a recent systematic review.13 A meta-analysis published in 2014 concluded with the
following statement:
The evidence does not support the first-line use of phenytoin. There is not enough evidence to support the
routine use of lacosamide. Randomized controlled trials are urgently needed.36
One RCT has recently been completed that evaluated the efficacy and safety of i.v. levetiracetam and
phenytoin in the management of CSE in children aged 3 months to 16 years.40,41 A second RCT recently
evaluated i.v. fosphenytoin, levetiracetam and sodium valproate in the management of CSE in children
(aged > 2 years) and adults.42
The Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE)
trial was a Phase IV, multicentre, parallel-group, randomised controlled open-label superiority trial
comparing i.v. levetiracetam with i.v. phenytoin.
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Rationale for research
Convulsive status epilepticus is the most common life-threatening neurological emergency in
childhood. It can result in significant morbidity, with acute and chronic impacts on the family and
health and social care systems. The current recommended first-choice second-line treatment in
children aged ≥ 6 months is i.v. phenytoin (fosphenytoin, which is a pro-drug of phenytoin in the USA).
However, this is not based on any robust RCT evidence and the drug is associated with significant and
potentially serious adverse reactions (SARs). Emerging evidence suggests that i.v. levetiracetam may be
effective as a second-line agent for CSE, and fewer ARs have been described. This trial was designed
to determine whether i.v. phenytoin or i.v. levetiracetam is the more effective and safer drug in the
treatment of childhood CSE.
Intervention
The EcLiPSE trial was an open-label trial using investigational medicinal products (IMPs) with
marketing authorisation in the UK. These became IMPs only when the packaging was opened in the
setting of this study. IMP provision was the responsibility of each site in accordance with standard
clinical practice. Both IMPs were stored in line with local requirements for general medicine supplies.
A single dose of the randomly allocated treatment was administered by i.v. infusion. The levetiracetam
dose was 40 mg/kg (with a maximum dose of 2500 mg) over 5 minutes, diluted to a maximum of
50 mg/ml with 0.9% sodium chloride. The dose of 40 mg/kg was based on the available published data
at the time of the full study application to the Health Technology Assessment programme in 2013. The
phenytoin dose was 20 mg/kg (with a maximum dose of 2000 mg) at a rate not exceeding 1 mg/kg/minute
(or > 20 minutes for doses of > 1 g), diluted with 0.9% sodium chloride to a maximum concentration of
10 mg/ml. This dose was based on national guidelines available in 2013.11
The allocated treatment was prepared and administered in accordance with standard clinical care, with
independent checking performed by two trained personnel. Trial-specific labelling was not required,
rather an approved ‘i.v. additive label’ was used. If the randomised treatment was discontinued prior
to administration of the full dose this was recorded. If CSE persisted at the end of the IMP infusion,
further medical management was decided by the local clinical team independent of the trial protocol
(Figure 1).
Objectives
The study objectives were to determine:
1. whether i.v. phenytoin or i.v. levetiracetam is the more efficacious second-line anticonvulsant for the
emergency management of CSE in children
2. whether or not i.v. levetiracetam is associated with fewer ARs or adverse events (AEs) than
i.v. phenytoin
3. the potential barriers and solutions to recruitment and consent in the EcLiPSE trial to inform future
trials with regard to recruiter training and trial conduct in this clinical setting (i.e. a nested
consent study).
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Time (minutes)
5
20
30
40
Patient transferred from ED when appropriateb
0 Phenytoin: 20 mg/kg
Maximum dose: as per local procedure
to a maximum of 2000 mg
Convulsive seizure starts
Clinical follow-up complete
Follow-up by local EcLiPSE team to:
• Provide information to families
• Obtain deferred consent for data entry
• Complete CRFs
First-line treatment administered in accordance with APLS guidelines
or personalised rescue care plana
Randomisation for second-line treatment and entry into the EcLiPSE trial
Blood levels for phenytoin/levetiracetam
Exit treatment arm of study to usual local treatment protocol
Complete 14-day safety follow-up and exit EcLiPSE
Dose:
> 1000 mg
and ≤ 1500 mg
Infusion:
between 20
and 30 minutes
Dose:
≤ 1000 mg
Infusion: 
over 20 minutes
Levetiracetam: 40 mg/kg
Infusion: over 5 minutes
Maximum dose: 2500 mg
Dose:
> 1500 mg
and
≤ 2000 mg
Infusion:
between 30
and 40 minutes
Within 24 hours after
second-line infusion started
1–2 hours after
second-line infusion complete 
24 hours after
second-line infusion started
14 days after
second-line infusion started
FIGURE 1 Study design. a, Administration of the first-line treatment may have occurred prior to arrival in the ED.
b, If a patient was randomised but not treated with a second-line anticonvulsant, follow-up would end at this point.
ED, emergency department.
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Chapter 2 Trial design and methods
Trial registration and ethics
The trial was approved by the National Research Ethics Service Committee North West – Liverpool
Central on 3 March 2016 (reference 15/NW/0090). The trial is registered as ISRCTN22567894
(registered 27 August 2015) and EudraCT identifier 2014-002188-13 (registered on 21 May 2014).
Participant inclusion and exclusion criteria
The full study protocol was published in 2017.2
Inclusion criteria
1. Males and females aged 6 months to 17 years 11 months (inclusive).
2. The presenting seizure was generalised tonic–clonic, generalised clonic or focal clonic status
epilepticus that requires second-line treatment to terminate the seizure.
3. First-line treatment was administered in accordance with APLS guidelines or the child’s personalised
rescue care plan to try and terminate the presenting seizure.
Eligibility notes
Patients with the following features were eligible for inclusion in the trial, assuming that all other
inclusion and exclusion criteria were met.
l Patients administered more than two doses of benzodiazepines, which is above the recommended
dose in APLS guidelines.
l Patients whose personalised rescue care plan included rectal paraldehyde as the first-line treatment.
l Patients receiving oral phenytoin or levetiracetam as part of their regular oral antiepileptic
drug regime.
Exclusion criteria
1. Absence, myoclonic or non-CSE, or infantile spasms.
2. Patients with a known or suspected pregnancy.
3. Patients with known contraindication or allergy to levetiracetam or phenytoin. This included when
the child’s personalised rescue care plan stated that the child never responded to, or had previously
experienced a SAR to, phenytoin, levetiracetam or both.
4. Patients with known renal failure (i.e. patients on peritoneal or haemodialysis, or with renal function
that is < 50% expected for age).
5. Previous administration of a second-line antiepileptic drug prior to arrival in the emergency
department (ED).
6. Patients known to have previously been treated as part of the EcLiPSE trial.
Recruitment
Thirty EDs (‘sites’) throughout Great Britain and Northern Ireland participated in the study. The sites
were selected from the membership of PERUKI [a collaborative paediatric emergency medicine (PEM)
research network].37 Participating sites included tertiary or district general hospitals with EDs that
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treat children only, or children and adults. A full list of participating centres is included in Appendix 3.
Centres were selected based on factors such as membership of PERUKI, site research infrastructure,
projected number of recruits based on the local population and proposed training strategy.
Screening commenced once a child arrived in the ED and received their first-line treatment for CSE.
A unique participant screening form was used and included an eligibility assessment and reasons for
non-randomisation where appropriate. If eligible, the participant was randomised to the trial.
Informed consent
The trial used research without prior consent (RWPC), also known as ‘deferred consent’, because of
the time-critical management of CSE, in accordance with regulatory requirements, RWPC guidance
and pre-trial research.43,44 Parents/legal representatives/patients (hereafter termed ‘participants’)
were approached once the child’s clinical condition was stable. This was ideally within 24 hours of
randomisation and prior to discharge from hospital, at which point written informed consent was
sought to continue data collection and use data already collected.
If consent was not sought prior to discharge the participant would be contacted within 5 working days
of randomisation by a delegated member of the research team and informed of the participant’s
involvement and details of the trial. Written information and a consent form were posted to the family.
The covering letter asked participants to return the enclosed form, indicating their consent for use of
the data already collected and continued participation in trial follow-up, within 4 weeks of the date
of the letter. If no response was received within 4 weeks, the covering letter verified that the participant
was included within the trial.
If the participant died before consent was sought, the site research team obtained information
from colleagues and bereavement counsellors to establish the most appropriate time and the most
appropriate practitioner to notify the parents/legal representative of their child’s involvement in the
research study.
When it was considered inappropriate to seek consent prior to the parent/legal representative’s departure
from hospital, the parent/legal representative was notified by a personalised letter and written information
about the trial from the most appropriate practitioner 4 weeks after randomisation. Wherever possible,
this practitioner would already be known to the family. The letter explained the EcLiPSE trial, reasons
for deferred consent, how to opt in or out of the trial and provided contact details if parents wished to
discuss the trial with a member of the research team (either in person or by telephone).
A second letter was sent to the bereaved family if there had been no response within 4 weeks of
the initial letter. The second letter included information about the EcLiPSE trial, reasons for deferred
consent and how to opt in or out of the trial. It also provided contact details if parents wished to
discuss the EcLiPSE trial with a member of the research team, either in person or by telephone.
Finally, it informed the family that the participant’s data would be included in the trial if no consent
form was returned within 4 weeks of the letter being sent, unless the family first notified the
site team.
Finally, there was also a qualitative mixed-method study involving participants to explore approaches
to recruitment and deferred consent. This is outlined in Chapter 4.
TRIAL DESIGN AND METHODS
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Randomisation
Participants were randomised to levetiracetam or phenytoin in a ratio of 1 : 1 using random variable
block sizes of two and four. A computer-generated randomisation schedule was produced by an
independent statistician who had no further involvement in the trial. Randomisation was stratified
by centre for logistical purposes. Centres were provided with sequentially numbered and EcLiPSE
trial-labelled randomisation packs. These were stored in an appropriate secure location within the
ED for ready access on presentation of eligible patients.
Randomisation packs were opaque brown cardboard tamper-proof A4 envelopes. The construction was
resistant to accidental damage or tampering and contents could not be viewed without fully opening
the envelope. Each pack was sequentially numbered and during randomisation the clinician/nurse used
the next sequentially numbered pack.
The case report form (CRF) that was completed at the patient’s bedside while the patient was in the
ED was included in the randomisation pack. The CRF was prepopulated with the centre code,
participant randomisation number and the randomly allocated treatment.
The randomisation pack should have been opened only once eligibility was confirmed on the screening
form. However, because of the time required to prepare the randomised treatment for infusion, this
was undertaken prior to when the infusion was required to avoid trial participation creating a delay in
treatment. This meant that some randomised participants would experience seizure cessation while the
infusion was being prepared.
Once randomised, the patient was administered the randomly allocated treatment, as required
clinically, to terminate seizure activity.
If the participant was randomised but the seizure terminated prior to infusion of the randomly
allocated treatment, the patient could subsequently be treated with the randomised treatment
allocation if the patient’s seizure restarted while still in the ED. However, if the patient’s seizure
restarted after leaving the ED, the randomised treatment could not be given.
If the randomised treatment was not administered while the patient was in the ED and instead the
comparator second-line was administered in error, the participant was still considered as recruited and
the randomisation number applied. The treatment administered was recorded, along with reasons why
it had not been possible to treat as per allocation.
If the patient had been given a RSI prior to administration of any second-line treatment the decision to
administer a second-line treatment was outside the EcLiPSE trial and the patient was treated as per
the site’s routine care.
Blinding
It was not possible to blind the trial interventions in the EcLiPSE trial because of the different times
required for their infusion. Although a double-dummy approach was considered, this would have
increased complexity during a paediatric emergency situation. Therefore, this was an open-label study.
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Outcome measures
Primary outcome
The primary outcome was time from randomisation to cessation of all visible signs of convulsive
seizure activity. All ‘visible signs of convulsive seizure activity’ was defined by cessation of all
continuous rhythmic clonic activity.
Secondary outcomes
The secondary outcomes were as follows:
1. the need for further anticonvulsants to manage CSE after administration of the trial treatment
2. the need for RSI because of ongoing CSE
3. the need for admission to a critical care unit (i.e. a high-dependency unit or a PICU)
4. the occurrence of SARs, including death, airway complications, cardiovascular instability (e.g. cardiac
arrest, arrhythmia and hypotension requiring intervention), extravasation injury (e.g. ‘purple glove
syndrome’) and extreme agitation.
Data collection
Follow-up
There were three time points for data collection in the EcLiPSE trial (see Figure 1). The first was in the
ED during the acute CSE treatment phase. The second was at 24 hours following the administration of
the randomised treatment, wherein data collected included further seizures, concomitant anticonvulsants
that may have been required to treat other acute seizures and ARs. The third and final time point was
undertaken 14 days after administration of the randomised treatment through review of hospital notes
and a single-sheet four-question questionnaire completed by the child’s parents. The questionnaire
included information on further hospital admissions and organ failure.
Blood samples
Samples were taken 1–2 hours after completion of the randomised treatment to measure drug levels, a
common practice when giving phenytoin.45 Levetiracetam levels were measured as part of trial conduct
by an accredited central laboratory. Measurement of phenytoin levels was undertaken in the
laboratory of each participating site as part of routine care.
Sample size
The sample size was calculated on the basis of published seizure cessation rates for phenytoin
(50–60%)14 and levetiracetam (76–100%).19–27 A sample size of 140 randomised and consented
participants per group, with a total of 183 events of CSE cessation, was required for a 0.05-level
two-sided log-rank test for equality of survival curves to detect an increase in seizure cessation rates
from 60% to 75% [a constant hazard ratio (HR) of 0.661] at 80% power. The sample size was increased
to 308 participants to allow for 10% loss to follow-up, which proved unnecessary. The final sample size
was 286 participants and the Independent Data and Safety and Monitoring Committee (IDSMC) and
Trial Steering Committee (TSC) were consulted before the decision to stop recruitment because of low
attrition and completeness of data. The difference to detect was influenced by the size of difference
deemed to be clinically important and convincing to change clinical practice. Although smaller differences
could also have been considered important, they needed to be balanced against the costs of the medicinal
products and the experience of delivering them within emergency care setting.
TRIAL DESIGN AND METHODS
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Trial management and oversight
Trial Management Group
The Trial Management Group (TMG) was responsible for the day-to-day practical and clinical aspects
of the trial. The team was multidisciplinary (see Appendix 2) and included the chief investigator, several
co-investigators, sponsor representatives, a patient and public involvement (PPI) contributor (see
Appendix 5) and members of the clinical trials unit.
Independent Data and Safety Monitoring Committee
The IDSMC was responsible for safeguarding the interests of the EcLiPSE trial participants, assessing
the efficacy and safety of the interventions throughout the trial and monitoring the overall progress
and conduct of the trial. The IDSMC comprised an independent paediatrician, an independent professor
of neurology and an independent statistician (see Appendix 1). The IDSMC met annually during the
course of the trial and provided recommendations to the TSC. The Haybittle–Peto approach was used
by the IDSMC as a guide to consider stopping the trial within interim reports with 99.9% CIs.
Trial Steering Committee
The TSC was responsible for providing overall oversight of the trial. The TSC comprised an
independent paediatrician, an independent consultant in PEM, an independent statistician and a
representative from the TMG (see Appendix 1). Co-sponsor representatives were invited to meetings
as observers. The TSC met annually throughout the study and remained masked to accumulating data
until the end of the trial. The TSC remained happy with trial progress and received monthly updates of
recruitment and progress. The TSC met in December 2017.
Both chairpersons of the TSC and the IDSMC supported a joint final meeting that was arranged to
coincide with the final results meeting. This meeting took place in Manchester on 9 July 2018 and the
results of the study were presented to all EcLiPSE trial team members of each participating site.
Internal pilot
The EcLiPSE trial included an 18-month internal pilot and involved five centres.
The 18-month period was chosen to allow five centres to be opened, be fully up to speed with trial
procedures and be achieving the optimal recruitment rate (assumed to be achieved 3 months after
opening). This time frame also allowed each site a minimum of 6 months of active recruitment at the
optimal level to demonstrate their recruitment rates and support prediction of trial activity into the
main phase of the trial.
Success criteria of the pilot were based on the below.
Recruitment
l If the predicted recruitment period is ≤ 36 months, then proceed to main trial.
l If the predicted recruitment period is between 36 and 48 months, then consider, and introduce,
ways to reduce this (e.g. increase the number of centres, address training needs or determine if new
evidence suggests that eligibility criteria could be widened) then proceed to main trial with amendments.
l If the predicted recruitment period is > 36 months and no obvious solutions exist, then abandon the
plan for the main trial.
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Deferred consent
l If the deferred consent rate is ≥ 80%, then proceed to the main trial.
l If the deferred consent rate is between 60% and 80%, and there is no clear association between
provision of deferred consent and the child’s outcome, then analyse reasons why patients/guardians
do not want to participate to identify any aspects amenable to change and proceed to the main
trial, as amended.
l If deferred consent is < 60%, then analyse reasons why patients/guardians do not want to
participate. If consent declination is associated with poor patient outcome (e.g. death), abandon the
main trial.
Completeness of primary outcome data
l If primary outcome data are available for > 90% of randomised and consented participants, then
proceed to the main trial.
l If primary outcome data are available for between 70% and 90% of randomised and consented
participants, then analyse reasons for missing data and identify whether or not any aspects are
amenable to change and proceed to the main trial, as amended.
l If primary outcome data are available for < 70% of participants randomised and consented, then
abandon the plan for the main trial.
Statistical methods
A detailed statistical analysis plan is available online [see NIHR Journals Library project web page
URL: www.journalslibrary.nihr.ac.uk/programmes/hta/12127134/# (accessed 25 September 2020)].
All analyses were undertaken with SAS® software, version 9.4 (SAS Institute Inc., Cary, NC, USA).
The primary analysis was based on a modified intention-to-treat principle. All randomised and
consented participants who received a second-line treatment were included in the analysis according
to their allocated treatment. Children who were randomised but whose CSE stopped without requiring
second-line treatment (and did not restart in the ED) were excluded. The safety analysis included the
same participants, grouped according to the actual treatment received. To avoid double counting, SAEs
were reported separately from AEs.
Statistical tests were two-sided at a 5% significance level and results are presented with 95% CIs. The
primary outcome was analysed using the log-rank test and is presented as a Kaplan–Meier curve. All
participants were followed up to cessation of CSE, with censoring used in the event of RSI or death. If
RSI was administered, time was censored at RSI plus 12 hours (i.e. 720 minutes). In patients who died
before cessation of CSE, time was censored at the time of death plus 48 hours (i.e. 2880 minutes). RSI
and death represent informative censoring and, therefore, the censoring times were inflated to signify
the negative outcome for the child with further sensitivity analyses. The sensitivity analyses considered
the robustness of the results to the primary analysis approach and included Gray’s test, treating RSI as
a competing risk, calculating time to cessation of CSE from start of infusion instead of randomisation
and censoring participants at the time of an additional second-line treatment after no response to the
allocated treatment. Additional analysis using a Cox proportional hazards model adjusted for baseline
characteristics of weight (i.e. < 12 kg, 12–36 kg or > 36 kg), sex and whether or not this was the
child’s first seizure. Two covariates (i.e. site of infusion and additional anticonvulsants given in parallel)
specified in the analysis plan were not included because they were measured after randomisation.
Additionally, centre (i.e. the site) could not be included as a factor in the Cox model because of the
lack of convergence. Schoenfeld residual plots were used to check the assumption of proportionality.
The binary secondary outcomes of need for further anticonvulsants, RSI and admission to critical care
were analysed using the chi-square test and presented with relative risks. Logistic regression models
TRIAL DESIGN AND METHODS
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were fitted as additional analyses to the primary chi-square tests, with adjustments as per the Cox
proportional hazards model. No adjustment was made for multiplicity for the secondary outcomes.
Baseline categorical data and AE data are summarised using numbers and percentages, and continuous
data are summarised as medians and interquartile ranges (IQRs). A post hoc analysis was undertaken
for the reasons underlying the further management of the presenting episode of CSE, the assessment
of which was carried out without knowledge of the allocated intervention.
Role of the funding source
The trial funder monitored trial progress and approved oversight committee membership, but had no
role in trial design, data collection, data analysis, data interpretation or writing of the report. The
corresponding author had full access to all data in the trial.
Changes to the protocol
The EcLiPSE trial opened to recruitment on version 3.0 of the protocol and closed on version 5.0.
Changes to the protocol are summarised in Appendix 4. In summary, the key changes from version 1.0
to version 2.0 included increasing the follow-up period to 14 days to collect longer-term safety data,
adding information that the primary outcome would be calculated from the time of randomisation and
providing additional clarifications on eligibility criteria. Amendments between subsequent versions
included clarification on dose, safety reporting, questionnaire administration and consent process.
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Chapter 3 Clinical effectiveness results
Parts of this chapter have been reused from Lyttle et al.1 This is an Open Access article distributedin accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license,
which permits others to copy and redistribute the material in any medium or format, provided the
original work is properly cited. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
Recruitment
Participants were recruited from a total of 30 sites, all EDs. Although 30 sites were formally opened,
two subsequently closed with neither site having recruited any participants. The first participant was
recruited from Alder Hey Children’s Hospital, Liverpool, on 22 July 2015 under version 3.0 of the
protocol and the last participant was recruited from Southampton General Hospital, Southampton,
on 7 April 2018 under version 5.0 of the protocol.
The five top-recruiting sites recruited 124 out of the 286 (43.4%) participants.
The observed site opening and participant recruitment rates closely followed those predicted (Figure 2).
Study commencement was delayed by approximately 6 weeks because of contractual issues between
the two co-sponsors of the study and, therefore, recruitment closed 6 weeks later than planned,
on 10 April 2018.
Participant screening and throughput are summarised in Figure 3.
Of the 1432 children screened for eligibility, 404 were randomised (i.e. the randomisation pack was
opened). A total of 1028 children were excluded before randomisation, including 972 children who did
not meet the eligibility criteria (see Tables 1 and 2). Reasons for not randomising 53 children who were
considered eligible included no trial-trained doctor available, loss of, or failure to, achieve i.v. access,
clinical judgement (e.g. child too sick) and treatment given before random allocation.
Inclusion criterion 2 (see Table 1) combined seizure type with the need for second-line treatment.
Table 2 looks at this inclusion criteria in greater detail to distinguish eligibility owing to seizure type
and ongoing need for second-line treatment.
Of the 404 children randomised, 93 did not require a second-line treatment. Of those children randomised
who did require a second-line treatment, 25 were excluded from the analysis as consent was either
incompletely documented (n= 6) or declined (n= 19). Table 3 provides the reasons why consent was declined.
Compliance with the intervention
Data on compliance (adherence) with treatment are shown in Tables 4 and 5.
Baseline characteristics
The baseline characteristics of the study participants were comparable (Table 6). However, the
levetiracetam-treated group comprised more participants in whom the presenting episode of CSE
[n = 69 (45%) vs. n = 49 (37%)] represented their first convulsive seizure ever, with a lower proportion
of participants with a chronic epilepsy, as evidenced by participants taking oral maintenance
antiepileptic drugs [n = 51 (34%) vs. n = 55 (41%)].
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Excluded from analysis
(n = 16)
• Consent incompletely documented, n = 5
• Declined consent, n = 11
• Lost to follow-up, n = 0
• Discontinued intervention, n = 0
Patients included in primary
outcome ITT analysis
(n = 134)
• Received phenytoin, n = 134
• Received levetiracetam, n = 0
Assessed for eligibility
(n = 1432)
Excluded from analysis
(n = 9)
• Consent incompletely documented, n = 1
• Declined consent, n = 8
• Lost to follow-up, n = 0
• Discontinued intervention, n = 0
Excluded before randomisation
(n = 1028)
• Did not meet eligibility criteria, n = 972
• Eligible but not randomised, n = 53
• Incomplete eligibility data, n = 3 
Patients included in primary
outcome ITT analysis
(n = 152)
• Received levetiracetam, n = 149
• Received phenytoin, n = 3
Excluded after randomisation. 
They did not require second-line
treatment because the presenting
seizure stopped; all provided
informed consent
(n = 93)
• Allocated to phenytoin, n = 42
• Allocated to levetiracetam, n = 51
Allocated to levetiracetam
(n = 161)
• Received levetiracetam, n = 149 
• Received phenytoin, n = 3 
• Consent to provide information withheld or 
    inadequate, n = 9
Allocated to phenytoin
(n = 150)
• Received phenytoin, n = 134 
• Received levetiracetam, n = 0
• Consent to provide information withheld or 
    inadequate, n = 16
(envelope opened)
Underwent randomisation
(n = 404)
(envelope opened and treatment given)
Required a second-line treatment
(n = 311)
FIGURE 3 Consolidated Standards of Reporting Trials (CONSORT) flow diagram. ITT, intention to treat.
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TABLE 3 Reasons for consent declined
Reason consent declined
Group
TotalLevetiracetam Phenytoin
Dad did not like the idea of being interviewed for the consent study. When it
was explained again that this was optional dad said he did not like the idea
1 0 1
Dad felt that he had been deceived and that consent should have been
asked first
1 0 1
Father did not want information to be used 1 0 1
Mum did not want sponsors or regulatory authorities to have access to the
child’s medical records
1 0 1
Not happy with DOB or gender to be used or have mum’s name written on
consent form
0 1 1
Parents felt patient had been through enough 1 0 1
Parents would like to put upsetting time in past 1 0 1
Too much going on and does not want any of their details collected 0 1 1
Language barrier – mum given information and understood brief concepts but
not enough to give informed consent
0 1 1
Not interested 0 1 1
Unclear reason. Parents have been given lot of information and patient was
diagnosed with a new condition since admission. Information overload
0 1 1
Stressed, patient very unwell 1 0 1
Do not like signing things 0 1 1
Social worker explained that this is a complex social care case – currently with
courts and they are unable to consent without court approval
0 1 1
Taken advice from solicitor due to ongoing litigation in respect to birth injury 0 1 1
No reason given 1 3 4
Total 8 11 19
DOB, date of birth.
TABLE 4 Treatment received by allocation
Patients randomised and consented
Group, n (%)
Total (N= 379),
n (%)Levetiracetam (N= 203) Phenytoin (N= 176)
Received no second-line treatment 51 (25.1) 42 (23.9) 93 (24.5)
Received allocated treatment 149 (73.4) 134 (76.1) 283 (74.7)
Received other second-line treatment to
that allocated
3 (1.5) 0 (0.0) 3 (0.8)
Received treatment followed by a second
second-line treatment
22a (14.5) 13a (9.7) 35a (12.2)
a Denominator is number of treated patients (levetiracetam, n= 152; phenytoin, n = 134; total, n= 286).
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TABLE 5 Trial compliance data
Compliance data
Group, n (%)
Total
(N= 286),
n (%)
Levetiracetam
(N= 152)
Phenytoin
(N= 134)
Patient given lower dose of trial treatment 8 (5.3) 4 (3.0) 12 (4.2)
Patient given higher dose of trial treatment 2 (1.3) 1 (0.8) 3 (1.1)
Dose administration shorter than expected 0 (0.0) 1 (0.8) 1 (0.4)
Dose administration longer than expected 27 (17.8) 34 (25.4) 61 (21.3)
Treatment prematurely discontinued 0 (0.0) 2 (1.5) 2 (0.7)
Unauthorised route of administration (intraosseous) 6 (4.0) 0 (0.0) 6 (2.1)
Received initial second-line treatment other than
that allocated
3 (1.5) 0 (0.0) 3 (0.8)
Received further second-line treatmenta 22 (14.5) 13 (9.7) 35 (13.6)
a Includes those who subsequently received the alternative trial treatment, or an additional dose of allocated
treatment, within 24 hours.
This table been reused from Lyttle et al.1 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY-NC-ND 4.0) license, which permits others to copy and redistribute the material in any
medium or format, provided the original work is properly cited. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
TABLE 6 Baseline demographic and seizure characteristics of the trial population
Demographic
Group
Levetiracetam (N= 152, 53%) Phenytoin (N= 134, 47%)
Sex, n (%)
Male 75 (49) 72 (54)
Female 77 (51) 62 (46)
Age
6 months to < 2 years, n (%) 65 (43) 53 (40)
2–11 years, n (%) 81 (53) 74 (55)
12–17 years, n (%) 6 (4) 7 (5)
Median (years) (IQR) 2.7 (1.3–5.9) 2.7 (1.6–5.6)
Range (years) 0.6–16.1 0.6–17.9
Weight (kg)
< 12, n (%) 52 (34) 42 (31)
12–36, n (%) 86 (57) 80 (60)
> 36, n (%) 14 (9) 12 (9)
Median (IQR) 12.1 (10.0–19.0) 12.0 (10.0–18.0)
Range 7.5–70.0 6.0–66.0
Participant’s first seizure, n (%) 69 (45) 49 (37)
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Protocol deviations
Protocol deviations were comparable across both treatment groups. Major and minor deviations are
shown in Table 7.
Major protocol deviations comprised:
l premature discontinuation of randomised treatment (none in the levetiracetam-treated group and
two in the phenytoin-treated group)
l duration of infusion shorter than expected (none in the levetiracetam-treated group and one in the
phenytoin-treated group)
l lower dose of the intervention administered (eight in the levetiracetam-treated group and four in
the phenytoin-treated group)
l missing data for primary outcome (two in both the levetiracetam- and phenytoin-treated groups).
TABLE 6 Baseline demographic and seizure characteristics of the trial population (continued )
Demographic
Group
Levetiracetam (N= 152, 53%) Phenytoin (N= 134, 47%)
Presenting seizure type, n (%)
Generalised tonic–clonic 107 (70) 105 (78)
Generalised clonic 12 (8) 7 (5)
Focal clonic 33 (22) 22 (16)
Seizure cause, n (%)a
Febrile convulsion 63 (41) 58 (43)
Seizure (pre-existing epilepsy) 46 (30) 46 (34)
First afebrile seizure 16 (11) 12 (9)
Central nervous system infection 6 (4) 7 (5)
Intracranial vascular event (bleed/stroke) 2 (1) 2 (1)
Traumatic brain injury 0 0
Substance misuse 1 (< 1) 0
Indeterminate 10 (7) 7 (5)
Other 27 (18) 26 (19)
Maintenance antiepileptic drugs at presentation, n (%)a
Levetiracetam 29 (15.9) 26 (19.4)
Sodium valproate 16 (10.5) 19 (14.2)
Carbamazepineb 12 (7.9) 10 (7.5)
Clobazamc 9 (5.9) 9 (6.7)
Topiramated 4 (2.6) 8 (6.0)
Phenytoin 0 (0.0) 1 (0.7)
Other 11 (7.2) 18 (13.4)
a Categories not mutually exclusive.
b Tegretol, Novartis, Basel, Switzerland.
c Frisium, Sanofi, Paris, France.
d Topamax, Janssen Pharmaceutica, Beerse, Belgium.
This table been reused from Lyttle et al.1 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY-NC-ND 4.0) license, which permits others to copy and redistribute the material in any
medium or format, provided the original work is properly cited. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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Primary outcome
Seizure cessation was achieved in 106 out of the 152 (70%) levetiracetam-treated participants and in
86 out of the 134 (64%) phenytoin-treated participants.
Table 8 provides the median time to seizure cessation from randomisation and Figure 4 shows the
Kaplan–Meier curve and log-rank test. As the event of interest (i.e. seizure cessation) is positive, the
lower curve indicates a shorter time to seizure cessation; however, there is no statistically significant
difference between the treatment arms (log-rank p-value > 0.05).
The unadjusted HR was 1.2 (95% CI 0.91 to 1.6; p = 0.2) in favour of levetiracetam. The Schoenfeld
residuals for the unadjusted model (p = 0.72) indicated the independency of time and the validity of
the proportionality assumption. The Schoenfeld residuals for the adjusted model indicated that the
assumption of proportionality for weight was not met (p = 0.05, p-value ranged from 0.27 to 0.71 for
other variables). The data were subgrouped according to weight category as per the baseline table
(i.e. < 12 kg, 12–36 kg and > 36 kg) and estimates from the adjusted model calculated (see Appendix 6,
Tables 15–29). The proportionality assumption within each subgroup of data was supported by the
Schoenfeld residuals. Direction of treatment effect was consistent across subgroups, CIs were wide
and results were not statistically significant. The treatment effect was increased for children in
the > 36 kg subgroup, but remained non-significant and numbers within this group are small.
A range of sensitivity analyses were considered to assess seizure cessation from the start of the infusion,
rather than from randomisation (see Appendix 7, Table 32) and the impact censoring regarding RSI and
death. The results demonstrated robustness of conclusions and are presented in Appendices 6 and 7.
TABLE 8 Time to cessation of all visible signs of convulsive seizure activity
Event
Group
Levetiracetam (N= 152) Phenytoin (N= 134)
Number of events (seizure cessation), n (%) 106 (69.7) 86 (64.2)
Number of censored times (RSI), n (%) 46a (30.3) 48b (35.8)
Median time (minutes) to cessation of seizure
from randomisation (IQR)
35 (20–NAc) 45 (24–NAc)
NA, not assessable.
a Of these 46 participants, three were administered RSI before the end of infusion.
b Of these 48 participants, 16 were administered RSI before the end of infusion.
c Upper quartiles could not be computed as not enough events were observed.
TABLE 7 Major and minor protocol deviations
Protocol deviation
Group, n (%)
Total (N= 286), n (%)Levetiracetam (N= 152) Phenytoin (N= 134)
Any protocol deviation 52 (34.2) 51 (38.1) 103 (36)
At least one major deviation 10 (6.6) 8 (6) 18 (6.3)
At least one minor deviation 43 (28.3) 45 (33.6) 88 (30.8)
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Secondary outcomes
The study comprised four secondary outcomes. These assessed the efficacy and safety of the two trial
interventions (Table 9).
One participant who was allocated and received phenytoin experienced a SAR. This was profound
hypotension, which was considered to be immediately life-threatening and responded to emergency
treatment. This participant also experienced a severe unexpected serious adverse reaction (SUSAR),
which manifested as a large increase in seizure frequency and marked sedation within 24 hours of
receiving phenytoin. The SUSAR was considered medically significant and the participant required
admission to the intensive care unit. The SUSAR resolved without complication.
Safety, tolerability and compliance
Two patients died in the study, but neither death was considered related to the randomised treatment.
One participant presented to the ED in a generalised tonic–clonic seizure and unconscious. Resuscitation
was immediate. The participant received levetiracetam (the randomised treatment) and then phenytoin,
followed by RSI with thiopentone (Archimedes, Reading, UK) because of abnormal posturing. The
participant died 36 hours following admission and a post-mortem examination revealed severe brain
oedema secondary to encephalitis. Consent for recruitment into the study was subsequently obtained
from the participant’s carers. The death was considered to be unrelated to the randomised treatment
by the principal investigator and chief investigator.
The second participant received phenytoin. The participant died and the results of the post-mortem
examination were not available prior to closure to recruitment to the study. The principal investigator
and chief investigator considered the death to be unrelated to the randomised treatment. Consent
was sought from the participant’s carers but had not been obtained by the time recruitment
to the study closed on 10 April 2018 and, therefore, this participant’s data are not included in
the analysis.
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FIGURE 4 Kaplan–Meier plot time from randomisation to seizure cessation. Product-limit survival estimates with
number of subjects at risk. This figure been reused from Lyttle et al.1 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license, which permits others
to copy and redistribute the material in any medium or format, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
CLINICAL EFFECTIVENESS RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
Adverse events and serious adverse events
A total of 51 AEs were reported in 39 out of the 286 participants. Some participants experienced more
than one AE. Forty-one of the AEs were classified as mild, nine as moderate and one as severe. Sixteen out
of 130 levetiracetam-treated participants, 18 out of 132 phenytoin-treated participants and four out of
24 participants who received both drugs experienced at least one AE. Each individual AE had a prevalence
of < 10%. In the levetiracetam-treated group (20 AEs in 16 participants), a psychiatric AE was reported
in 12 participants (agitation in 11 and hallucinations in one). In the phenytoin-treated group (23 AEs in
18 participants), a cardiovascular AE was reported in eight participants, an extravasation/administration
site reaction AE in seven (severe in one) and an agitation AE in four. In the group that received
levetiracetam and phenytoin (eight AEs in four participants), an extravasation/administration site reaction
was reported in three. The full list of reported AEs is shown in Table 10.
Five SAEs were reported in four participants [including one participant who experienced two SAEs
(participant 00133027)]. In three participants, the SAE was considered unrelated to the intervention,
and one each was considered to be possible and probable (Table 11).
An additional follow-up questionnaire was completed by sites and the families of participants who had
been randomised, treated and consented to take part in the study. The questionnaire was completed
2 weeks following randomisation. Results are shown in Table 12.
Only 74 (25.9%) families completed their 14-day follow-up questionnaire. As documented in the
internal meeting minutes, 8 May 2018, details for these questionnaires are not presented within this
report because of the low response rate.
TABLE 9 Secondary outcomes and 14-day follow-up
Secondary outcome
Group, n (%)
Unadjusted RR
(95% CI) p-value
Levetiracetam
(N= 152)
Phenytoin
(N= 134)
Need for further anticonvulsantsa 57 (37.5) 50 (37.3) 1.01 (0.74 to 1.36) 0.97
Need for further anticonvulsants for
the presenting CSEb
24 (15.8) 20 (14.9) 1.06 (0.61 to 1.83) 0.84
Need for further anticonvulsants for a
subsequent seizure (within 24 hours)b,c
14 (9.2) 17 (12.7) 0.72 (0.37 to 1.4) 0.33
RSI to terminate an ongoing seizure 44 (30.0) 47 (35.1) 0.83 (0.59 to 1.16) 0.27
Admission to critical care 97 (63.8) 72 (53.7) 1.19 (0.97 to 1.45) 0.08
SAR 0 2d
14-day follow-up
Discharged from hospital 145 (95.4) 130 (97.0)
Readmitted to hospital 12 (7.9) 10 (7.5)
Patient died 1 (0.7) 1 (0.8)
Organ failure 1 (0.7) 0 (0.0)
RR, relative risk; SUSAR, suspected unexpected serious adverse reaction.
a Includes all instances of a further anticonvulsant being given in the first 24 hours, including for the presenting
episode of CSE, subsequent seizures or for prophylaxis.
b Post hoc analysis. Assessment conducted without knowledge of the allocated intervention.
c Excludes nine participants for whom data were unavailable.
d Two events (reactions) in one participant, one of which was a SUSAR.
This table been reused from Lyttle et al.1 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY-NC-ND 4.0) license, which permits others to copy and redistribute the material in any
medium or format, provided the original work is properly cited. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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Laboratory parameters (haematological, biochemical analysis and urinalysis)
Laboratory analyses in the trial protocol were limited to measurements of blood levels of levetiracetam
and phenytoin in the randomised, treated and consented participants. Blood samples were obtained
between 1 and 2 hours after completion of infusion of the two treatments. Biochemistry laboratories
in each site processed the samples in accordance with their standard operating procedures. The reference
ranges for blood levels of levetiracetam were provided by a single central laboratory that analysed
all of the samples of levetiracetam-treated participants. The reference ranges for blood levels of
phenytoin were provided by the biochemistry department of each participating site that analysed
samples of its phenytoin-treated participants.
A total of 192 participants underwent measurement of a blood level [96 participants in the
levetiracetam-treated group (63.2%) and 96 participants in the phenytoin-treated group (77.7%)]
and the results are shown in Figures 5 and 6.
TABLE 10 Adverse events
AE
Group
Total (N= 286)
Levetiracetam
(N= 132) Phenytoin (N= 130) Both drugs (N= 24)
Events, n
Patients,
n (%) Events, n
Patients,
n (%) Events, n
Patients,
n (%) Events, n
Patients,
n (%)
Agitation 11 11 (8.3) 4 4 (3.1) 0 0 (0.0) 15 15 (5.2)
Hypotension 2 2 (1.5) 3 3 (2.3) 1 1 (4.2) 6 6 (2.1)
Catheter site
related
1 1 (0.8) 1 1 (0.8) 3 2 (8.3) 5 4 (1.4)
Extravasation 0 0 (0.0) 4 4 (3.1) 1 1 (4.2) 5 5 (1.75)
Tachycardia 1 1 (0.8) 3 3 (2.3) 1 1 (4.2) 5 5 (1.75)
Rash 2 2 (1.5) 1 1 (0.8) 0 0 (0.0) 3 3 (1.1)
Hypertension 0 0 (0.0) 2 2 (1.5) 0 0 (0.0) 2 2 (0.7)
Reaction to
ceftriaxonea
0 0 (0.0) 0 0 (0.0) 1 1 (4.2) 1 1 (0.4)
Confused 1 1 (0.8) 0 0 (0.0) 0 0 (0.0) 1 1 (0.4)
Decreased
consciousness
0 0 (0.0) 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Hallucination 1 1 (0.8) 0 0 (0.0) 0 0 (0.0) 1 1 (0.4)
Infusion site
erythema
0 0 (0.0) 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Mechanical
ventilation
complication
0 0 (0.0) 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Pallor 0 0 (0.0) 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Stridor 0 0 (0.0) 0 0 (0.0) 1 1 (4.2) 1 1 (0.4)
Vomiting 0 0 (0.0) 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Wheezing 1 1 (0.8) 0 0 (0.0) 0 0 (0.0) 1 1 (0.4)
Total 20 16 (12.1) 23 18 (13.9) 8 4 (16.7) 51 38 (13.3)
a Rocephin, Roche Holding AG, Basel, Switzerland.
This table been reused from Lyttle et al.1 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY-NC-ND 4.0) license, which permits others to copy and redistribute the material in any
medium or format, provided the original work is properly cited. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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TABLE 11 Serious adverse events
SAE number Description
Preferred term
(System Organ Class)
Treatment
received Seriousness Severity Expectedness
Relationship assessment
Outcome
Principal
investigator
Chief
investigator
00133007-001 Attended ED fitting. Randomised to
levetiracetam, but given phenytoin.
Stopped self-ventilating and required
RSI and was intubated. CT showed
fractured VP shunt and required
urgent shunt revision. Taken to theatre
25 November 2015 at 02.45. Shunt
revision complete. Admitted to PICU
for < 24 hours. Admitted to
neurosurgical ward until
30 November 2015
Device malfunction
(general disorders and
administration site
conditions)
Phenytoin Prolonged
existing
hospitalisation
Moderate Unexpected Unrelated Unrelated Resolved
00133027-005 Patient weaned off sedation on
22 March 2017. At 13.55 patient
started having seizure episodes.
Documented in notes that the patient
had approximately 40 seizures
until phenobarbital given at 18.10,
22 March 2017. No further seizures
but conscious level decreased until
18.00, 26 March 2017
Seizure (nervous
system disorders)
Phenytoin Medically
significant or
important
Moderate Unexpected Unlikely Possibly Resolved
00133027-006 Patient became hypotensive at 01.45,
22 March 2017. Patient given fluid
boluses as documented on concomitant
medication form. Patient remained
hypotensive and so given adrenaline
infusion. Hypotension resolved
completely (26 March 2017). No
further problems
Hypotension
(vascular disorders)
Phenytoin Immediately
life-threatening
Moderate Expected Possibly Probably Resolved
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TABLE 11 Serious adverse events (continued )
SAE number Description
Preferred term
(System Organ Class)
Treatment
received Seriousness Severity Expectedness
Relationship assessment
Outcome
Principal
investigator
Chief
investigator
00133029-008 Patient randomised and given
levetiracetam. Noted to have only
slight twitching after. Patient then
started having decorticate/decerebrate
posturing. RSI. Desaturated and
bradycardia owing to ET tube
problems. No ETC02 reading,
reintubated but ventilation difficult
causing desaturation and bradycardia.
Arrest CPR commenced
Cardiac arrest
(cardiac disorders)
Levetiracetam Immediately
life-threatening
Prolonged
existing
hospitalisation
Severe Unexpected Unrelated Unrelated Resolved
00243026-002 Attended the ED fitting and
unconscious. Pupils equal and reactive
but sluggish. Tolerating airway. CT
showed massive raised intracranial
pressure. Pupils become fixed and
dilated just before being taken to
emergency theatre. Oral secretions
positive for mycoplasma pneumoniae
Intracranial pressure
increased (nervous
system disorders)
Phenytoin and
levetiracetam
Immediately
life-threatening
Severe Unexpected Unrelated Unrelated Fatal
CPR, cardiopulmonary resuscitation; CT, computerised tomography; ET, endotracheal; ETCO2, end-tidal carbon dioxide; VP, ventriculoperitoneal.
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TABLE 12 Follow-up questionnaires
Follow-up Allocation Yes, n (%) No, n (%)
Information not provided
in patient notes, n (%)
Unknown or
missing, n (%) Total, n (%)
Discharged
from hospital
Levetiracetam 145 (95.4) 7 (4.6) 0 (0) 0 (0) 152 (53.15)
Phenytoin 130 (97) 4 (3) 0 (0) 0 (0) 134 (46.9)
Total 275 (96.1) 11 (3.8) 0 (0) 0 (0) 286 (100)
Readmitted
to hospital
Levetiracetam 12 (7.9) 81 (53.3) 25 (16.4) 34 (22.4) 152 (53.1)
Phenytoin 10 (7.5) 64 (47.8) 19 (14.2) 41 (30.6) 134 (46.9)
Total 22 (7.7) 145 (50.7) 44 (15.4) 75 (26.2) 286 (100
Patient died Levetiracetam 1 (0.7) 111 (73) 22 (14.5) 18 (11.8) 152 (53.1)
Phenytoin 1 (0.7) 93 (69.4) 20 (14.3) 20 (14.9) 134 (46.9)
Total 2 (0.7) 204 (71.3) 42 (14.7) 38 (13.3) 286 (100)
Organ failure Levetiracetam 1a (0.7) 110 (72.4) 20 (13.2) 21 (13.8) 152 (53.1)
Phenytoin 0 (0) 98 (73.1) 16 (11.9) 20 (14.9) 134 (46.9)
Total 1 (0.3) 208 (72.7) 36 (12.6) 41 (14.3) 286 (100)
a Organ not specified.
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FIGURE 5 Levetiracetam blood levels.
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Chapter 4 Nested consent study
Background
Convulsive status epilepticus is a medical emergency that has insufficient time to obtain informed
consent within the therapeutic window. The use of RWPC (also known as deferred consent) in the
EcLiPSE trial was supported by parents who took part in trial feasibility work.43
A nested study was designed to identify potential barriers and solutions to recruitment and consent in
the EcLiPSE trial, and to inform recruiter training on recruitment, consent, trial conduct and future
trials in this setting.
Objectives
Consent study objectives were to explore:
l how information about the trial and RWPC was exchanged during recruitment discussions
l parents’ and practitioners’ views and experiences of RWPC and consent decision-making
l the impact of an unblinded trial design.
We included a strand of work that aimed to develop trial recruiter training on RWPC using
recommendations made by parents in the feasibility study and related guidance.43,46–49 Our objective
was to evaluate the effectiveness of the EcLiPSE trial site initiation visit (SIV) training on practitioners’
confidence in recruitment, consent and trial conduct.
Methods
Study design
The consent study used a mixed-methods approach,50,51 involving parents of randomised participants
and EcLiPSE trial practitioners. The design and development of the consent study, including
recruitment strategy, questionnaires and topic guides, were informed by previous work43,46 in paediatric
emergency and critical care in the NHS. EcLiPSE trial feasibility work43 was used to develop participant
information and practitioner training materials.
All EcLiPSE trial sites were eligible for inclusion in the consent study, which involved the following
research methods:
l recorded trial recruitment and consent discussions between parents and EcLiPSE trial practitioners
l parent questionnaires completed after EcLiPSE trial consent discussions (including those who
decline consent)
l telephone interviews with parents approximately 1 month after hospital discharge
l telephone interviews with the site principal investigator or research nurse within the first 12 months
of site opening
l focus groups with practitioners at the end of the first year
l a semistructured questionnaire with practitioners administered before and after SIV training
l an online questionnaire of practitioners in final phase of the trial (approximately 8 months before
trial closure).
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Participants
We aimed to collect parent questionnaires at all sites throughout trial recruitment. Based on previous
research,43,44 we anticipated interviewing approximately 15–25 parents/legal representatives, conducting
6–10 focus groups and 10 additional practitioner interviews to reach data saturation (i.e. the point where
no new major themes are discovered in analysis). We planned to collect recorded trial discussions at all
sites for the first 4 months of the trial or until data saturation point. We aimed to include practitioners
at all sites in the online survey and all staff attending each SIV in the training evaluation.
Eligibility
Parents
Parents (including legal representatives) who did and did not consent to their child’s participation
in the trial were eligible to take part in the consent study, unless they were unable to speak or
read English.
Practitioners
All practitioners involved in screening, recruiting, randomising and consenting parents/legal
representatives during the trial were eligible to take part in the consent study. Those not intending to
stay for the full SIV training were excluded from the SIV questionnaire element.
Recruitment
Recruitment to recorded trial discussions, parent questionnaires and interviews
As described in Chapter 2, the principal investigator, research nurse or other designated member of the
site research team approached the parent/legal representative to discuss the trial and seek consent as
soon as possible after completion of trial treatment (ideally within 24 hours of randomisation). During
this discussion, the principal investigator/research nurse briefly explained the aims of the consent
study and sought verbal permission for audio-recording of trial discussions. If permission was declined
the recruitment discussion was not recorded. If permission was given the recruiter activated an audio-
recorder. Written consent was then sought for all consent study elements as part of the EcLiPSE trial
consent process. This included written consent for the use of recorded trial discussion data, as well as
consent to complete a questionnaire before their child was discharged from hospital and to take part
in an interview approximately 1 month later.
Parents were asked to place the completed questionnaires in a sealed, stamped, addressed envelope
and return it to the EcLiPSE trial practitioner to post to the consent study team. There was also a link
to an online version of the questionnaire at the top of the paper questionnaire, enabling parents to
complete the survey online if preferred. Recruitment for questionnaires took place throughout the
active trial recruitment phase. In the rare instance that consent was not sought prior to discharge or
before the participant was transferred to another hospital, the questionnaire was sent to parents/legal
representatives along with the parent/legal representative information sheet and consent form to
complete. We asked trial recruiters to record all trial discussions (e.g. an initial discussion followed by
a full trial discussion after the family had considered the trial information), which were then uploaded
to a secure website for transcription. LR made contact with families to arrange telephone interviews
within 1 month of consent. Initially, parents’ expressions of interest to participate were responded to in
sequential order. As trial recruitment progressed, we stopped interviewing parents from high-recruiting
sites and purposively sampled across all recruiting sites to help ensure sample variance.
Recruitment to practitioner focus groups and interviews
LR e-mailed selected sites and invited practitioners to participate in a telephone interview or focus
group. Selection of sites was based on accrual rates (i.e. high and low rates) and recruitment issues
identified in the ongoing analysis of recorded trial discussion, parent questionnaires and interviews.
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Verbal consent was sought, including consent for recorded trial discussions. All focus groups were
facilitated by LR who sought audio-recorded verbal consent from participants before each focus
group began.
Recruitment to the site initiation visit evaluation
The trial co-ordinator (AH) liaised with the site principal investigator or research nurse to invite
all relevant staff to the SIV. KW, LR or AH provided a brief description of the evaluation before
the opening presentation and invited practitioners who intended to stay for the full training to
participate by completing part A of the questionnaire before training and part B at the end of training.
Questionnaire completion was taken as indication of consent. Personal details were not requested to
ensure anonymity.
The trial co-ordinator (AH) e-mailed all eligible sites (28 out of 30 sites because two had closed)
8 months before the scheduled trial end date, and invited staff involved in the EcLiPSE trial to
complete an online questionnaire [see appendix on the NIHR Journals Library project web page:
URL www.journalslibrary.nihr.ac.uk/programmes/hta/12127134/#/ (accessed 28 September 2020)].
MDL sent e-mail reminders on behalf of the trial team and PERUKI. It was anticipated that some
of the same staff who took part in a telephone interview or focus groups would also complete the
online questionnaire.
Conduct of interviews and focus groups
LR began interviews and focus groups with parents and practitioners with a description of the consent
study aims. The interview commenced using an interview topic guide (see Appendix 8). Respondent
validation was used to add unanticipated topics to the topic guide as interviewing and analysis
progressed. After the interview, participants were thanked for their time.
Any distress during the parent interviews was managed with care and compassion and participants
were free to decline to answer any questions that they did not wish to answer or to stop the
interviews at any point.
Transcription
Digitally recorded trial discussions were transcribed verbatim by a professional transcription company
(VoiceScript Ltd, Bristol, UK). Transcripts were anonymised and checked for accuracy. All identifiable
information, such as names (e.g. of patients, family members or the hospital their child had been
admitted to), were removed.
Data analysis
Qualitative data
LR (a psychologist) led the analysis with assistance from KW (a sociologist). Qualitative focus group
and interview data analysis was interpretive, and iterative analysis was based on thematic analysis, a
method for identifying, analysing and reporting patterns (or themes) within data. Utilising a thematic
analysis approach, the aim was to provide accurate representation of parent and practitioner views
to address the study aims and objectives. This approach allows for themes to be identified at a
semantic level (i.e. surface meanings or summaries) or at a latent level (i.e. interpretive, theorising
the significance of the patterns and their broader meanings and implications).50 NVivo 10 software
(QSR International, Warrington, UK) was used to assist in the organisation and coding of data.
Quantitative data
LR entered all parent and practitioner online questionnaire and SIV training questionnaire data into
SPSS version 26 (SPSS Inc., Chicago, IL, USA). Descriptive statistics are presented with percentages and
the chi-squared test for trend.
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For the SIV training questionnaire analysis, we used paired samples t-test and Wilcoxon signed-ranks
test (95% CI), as appropriate. Questionnaires with recruitment and consent-related data missing were
excluded from the analysis. To investigate the presence of informative missing data, the results of
those who completed only part A of the questionnaire were compared with those who completed parts
A and B of the questionnaire. This was also undertaken for those who completed only the ‘after’
questionnaire.
Data synthesis
Our approach to synthesising qualitative and quantitative data52 drew on the constant comparative
method.53,54 As part of an iterative process, KW and LR used early findings during trial conduct to
create updates via newsletters for EcLiPSE trial recruiters and brief feedback sessions at the end of
each focus group. These outputs contained recommendations to assist ongoing approaches to
recruitment and consent in the EcLiPSE trial.
Results
Participants: parents
Two hundred and eighteen parents of the 289 (75%) children randomised and treated in the EcLiPSE
trial consented to participate in some aspect of the consent study. A total of 212 out of 218 (97%)
parents consented to complete a questionnaire and in 13 instances two parents completed a
questionnaire for one child. A total of 143 out of 212 (67%) paper-version questionnaires were
received (Figure 7). No parents chose to complete the questionnaire using the online version.
Recorded trial discussions and interview elements closed in August 2017 (with 193 patients treated
and randomised at that stage of the trial) as we reached the data saturation point.55 Just under half
(95/193, 49%) of eligible parents gave consent for the recorded trial discussion. Of these recorded
Questionnaire
Consented: n = 212/289, 73%
Declined: n = 45/289, 15% 
Not approached: n = 11/289, 3%
Not received: n = 66/212, 31%
Questionnaires received: n = 143/212, 67% 
Mother: n = 93/143, 65% 
Father: n = 39/143, 27% 
Recorded trial discussion
Consented: n = 95/193, 49%
Declined: n = 98/193, 51%
Recordings received and analysed: n = 76/95, 80% 
Telephone interview
Consented: n = 114/193, 59%
Declined: n = 79/193, 31%
Contacted for telephone interviews: n = 59/114, 51%
No response to contact: n = 10/59, 16%
Incorrect details: n = 8/59, 13%
Declined when contacted: n = 11/59, 18% 
Took part in interview: n = 30
Mothers: n = 25, 83%
Fathers: n = 5, 16% 
FIGURE 7 Parent characteristics by method.
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discussions, 76 out of 95 (80%) were received and analysed. Of 114 (59%) of the 193 eligible parents
who agreed to be approached for interview, 59 (51%) were invited to participate in an interview by
telephone or e-mail. Of these, eight (13%) had incorrect contact details, 10 (16%) did not respond and
11 (18%) declined to interview on telephone contact. Interview and recorded trial discussions data
were obtained from 17 out of 25 (68%) sites. Of these, 36 out of 76 (47%) recorded trial discussions
were led by doctors and 19 out of 76 (25%) conversations were led by nurses or research nurses. Most
(45/76, 60%) practitioners recorded one trial discussion, 24 out of 76 (31%) recorded two parts of a
trial discussion and 7 out of 76 (9%) recorded three or more parts. In 37 (49%) cases, it was clear that
only the second part of the conversation had been recorded. We obtained a full data set (i.e. the
questionnaire, recorded trial discussions and parental interview) for 19 families.
Participants: practitioners
We interviewed EcLiPSE trial principal investigators (n = 4) and lead research nurses (n = 6) who were
the main staff involved in recruitment discussions with parents within their first year of site opening.
Telephone interviews took place 8–18 months post SIV training (mean 11 months, 345 days; range
260–577 days) and 5–16 months after site opening (mean 8 months, 265 days; range 168–490 days).
A total of 36 practitioners (i.e. 20 nurses and 16 doctors) took part in one of six focus groups held
13–18 months post SIV (mean 14 months, 455 days; range 400–574 days) and a mean of 12 months
(mean 374 days; range 329–420 days) after site opening.
The SIV evaluation involved 26 out of 30 (87%) sites. A total of 149 out of 312 (47%) staff were
eligible for inclusion, as they anticipated staying for the full site initiation meeting and completed
a questionnaire. Clinical commitments had an impact on staff’s ability to attend the entire SIV.
Consequently, 24 out of 149 (16%) questionnaires were partially completed and excluded from the
analysis because of missing data.
A total of 199 practitioners from 29 out of the 30 (97%) sites completed the online questionnaire
approximately 8 months before the end of the trial.
See Appendix 10 for consent study participant characteristics.
We present consent study findings under key themes identified in the analysis of parent and
practitioner data.
Trial acceptability and challenges: practitioner perspectives
For many hospitals, the EcLiPSE trial was the first clinical trial to be led by their ED. In the early
stages of the design of the EcLiPSE trial, the trial team recognised practitioner concerns about the
acceptability of RWPC. A training package was, therefore, developed using parents’ perspectives from
the EcLiPSE feasibility study40 and CONseNt methods in paediatric Emergency and urgent Care Trials
(CONNECT) guidance.48 The aim was to help provide practitioners with confidence in recruitment and
RWPC in the EcLiPSE trial.
Practitioner perspectives before trial recruitment
Before site initiation training, 33 out of 118 (28%) practitioners who completed a questionnaire
indicated that they had concerns about recruiting participants to the trial. A higher proportion of
practitioners (48/120, 40%) was concerned about seeking RWPC (Table 13). During interviews and
focus groups practitioners described how their concern arose from lack of knowledge and experience
of RWPC. Some staff were apprehensive about the acceptability of RWPC and ‘quite concerned how
parents would take that [RWPC]’ (focus group 4, female, nurse, P1) and about ‘how to approach it with
the parents’ (practitioner telephone interview, female, lead research nurse, P3) after their child had
been entered into the trial.
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Interestingly, previous experience with RWPC was not associated with concerns about recruitment or
seeking consent, suggesting that concerns may have arisen from issues other than the consent process.
Sixty-nine out of 115 (60%) practitioners who completed the questionnaire anticipated that there
would be practical or logistical difficulties in conducting the EcLiPSE trial. This included concerns about
adequate research support to conduct consent discussions with families, particularly ‘over the weekend’
(SIV questionnaire part A, female, doctor, P55), as well as the challenge of training all relevant staff
across departments. In focus groups, doctors discussed their concerns about using a trial protocol in an
emergency resuscitation situation, while not compromising the clinical care of critically ill children:
I thought, oh God, this sounds horrendous. Literally I was thinking, how is this going to work? This is
going to be a nightmare.
Focus group 3, female, doctor, P3
As the number of eligible patients per site was expected to be fairly small (i.e. approximately 0.5
patients per month), practitioners referred to the anticipated challenge of maintaining trial awareness
to ensure that eligible patients were not missed. Principal investigators were most concerned about
engaging and motivating all staff to maximise trial success:
Difficult to control for other people who may be less interested in our department being involved.
SIV questionnaire part A, female, doctor, P121
Practitioner perspectives after training and experience of recruitment
As shown in Appendix 9, Tables 38 and 39, improved levels of confidence were observed for all four
questionnaire statements, regardless of whether or not practitioners had prior experience of RWPC.
It was notable that following training 82 (66%) practitioners felt that their confidence in explaining the
study to families had improved, whereas 90 (72%) practitioners felt more confident in explaining RWPC
to families. Approximately half of the practitioners also indicated that their confidence in explaining
randomisation (47%) and addressing parents’ objections to randomisation (51%) had improved.
Questionnaire part B (after training) free-text responses, as well as interview and focus group
discussions, indicated that the EcLiPSE trial training had addressed many of the practitioners’ concerns
about recruitment and RWPC. After training, many described how the trial and its approach to
consent seemed more ‘feasible’ (SIV questionnaire part B, female, doctor, P128) and ‘logical and
TABLE 13 Concerns about recruitment and consent in the EcLiPSE trial by practitioner experience of RWPC (n= 125)
Question Yes, n (%)a No, n (%)a Odds ratio 95% CI p-value
Do you have any concerns about
recruiting to the EcLiPSE trial?
33 (28) 85 (72)
Experienced in RWPC 4 (19) 17 (71) 0.54 1.17 to 1.74 0.296
Not experienced in RWPC 28 (30) 64 (70)
Do you have any concerns about seeking
consent for the EcLiPSE trial?
48 (40) 72 (60)
Experienced in RWPC 6 (26) 17 (74) 0.46 0.17 to 1.30 0.128
Not experienced in RWPC 40 (43) 52 (57)
a Percentages are rounded to the nearest whole number.
Notes
Missing responses: question 1 n= 7 (5.6%) and question 2 n = 5 (4.0%).
Missing responses for cross-tabulation by experience of RWPC: question 1 n= 12 (9.6%) and question 2 n= 10 (8.0%).
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straightforward’ (SIV questionnaire part B, female, nurse, P30). Research nurses, in particular, valued
the examples of tailored communication, such as the ‘terminology used to explain this to families’
(SIV questionnaire part B, female, nurse, P109), as well as ‘see how nurse handled difficult questions’
from parents (SIV questionnaire part B, female, nurse, P27). During telephone interviews, research
nurses also commented on the training:
There are some good sort of one-line quotes that you can take from it.
Practitioner telephone interview, female, lead research nurse, P4
Although fewer logistical concerns were expressed after training, some practitioners restated concerns
about staff availability to cover consent discussions with families 7 days per week. Questionnaire,
interview and focus group participants also highlighted the challenge of disseminating training to
relevant ED staff, including new doctors at the trainee rotational changeover, and having sufficient
staff trained to cover consent-seeking during evenings, weekends and over busy periods.
Despite these challenges, principal investigators and research nurses took the lead in providing regular
or bespoke training sessions to help ensure that all relevant staff were able to screen, recruit or
seek consent:
I’ve trained new people who’ve joined the team . . . then just the ongoing simulation training . . . and
making sure people are still familiar with the protocol.
Practitioner telephone interview, male, doctor, P2
In focus groups, practitioners suggested that the trial management team could provide recruitment
and consent support through study updates, advice (when required) and recruitment training tips from
the ongoing consent study. This support was provided through regular contact and newsletter updates,
which included access to training materials online and on a USB (universal serial bus) provided to
each site principal investigator. Practitioners described how trial team support and access to training
materials facilitated dissemination of training to new staff. In the online questionnaire, 8 months before
the end of trial recruitment, practitioners involved in any element of the EcLiPSE trial were asked to
select the statements that they felt were relevant to their site. The majority of practitioners indicated
that the trial was running well, which was supported by trial recruitment data (i.e. recruiting to target
with a 95% consent rate). Only two practitioners (2/199, 1%) reported that anxieties about RWPC
were a barrier to recruitment. Some practitioners reported that staff shortages had led to patients
being missed and some (6%) indicated that training was not frequent enough.
Trial acceptability: parents’ perspectives
Recorded trial discussion and interview data showed that the majority of parents were first aware of
their child’s involvement in the study after the emergency situation had passed. At an early point in
trial discussions, practitioners provided a brief explanation of the reasons why informed consent had
not been sought. These explanations were often consistent with CONNECT guidance48 and related SIV
training provided to practitioners during site training.
The majority of parents found the EcLiPSE trial to be acceptable and parents were ‘happy’ for their
child ‘to participate’ in the trial (recorded trial discussion 6, parent). These findings are supported by all
sources of data collected, including practitioners’ descriptions of consent discussions with parents and
the high consent rate for the EcLiPSE trial.
Consistent with previous studies in an emergency setting,47,56 just over one-third of parents who
completed the questionnaire were initially surprised to find out that their child had already been
entered into the trial without their prior consent (Table 14).
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This experience was also described by parents who were interviewed. However, these parents
described their surprise was momentary, as practitioner explanations about why informed
consent could not be sought in an emergency situation had addressed any initial surprise
or concern:
I think the only thing I really found surprising was the whole informing you about it afterwards, but he
explained all that and I do understand why that was done . . . when he explained it all, I mean it makes
sense. It’s not the situation to start having discussions, it’s an emergency situation.
Parent interview, mother, P14
The majority (129/143, 90%) of parents who completed a questionnaire indicated that they were
satisfied with the consent process. In addition, they indicated that the timing of the consent discussion
was appropriate [statement 1: 129/143 (90%)], that trial information was straight forward and easy
to understand [statement 3: 139/143 (97%)], and that they understood the reasons why consent had
been sought after treatment had been given [statement 4: 139/143 (97%)]. Moreover, responses to
statements 8–12 suggest that parents felt that they made voluntary consent decisions, which were not
inappropriately influenced by others (see Table 14).
TABLE 14 Parental questionnaire responses regarding the EcLiPSE trial consent process (n = 143)
Statement
number Statement
Response, n (%)a
Agree
Neither agree
nor disagree Disagree
1 The practitioner checked that it was a convenient
time to discuss research before discussing the
EcLiPSE trial
129 (90) 9 (6) 5 (4)
2 I was initially surprised to find out that my child had
already been entered into the EcLiPSE trial
56 (39) 49 (34) 38 (27)
3 The information I received about the EcLiPSE trial
was clear and straightforward to understand
139 (97) 4 (3) 0 (0)
4 I understood why consent for my child’s participation
in the EcLiPSE trial was sought after the treatment
had been given
139 (97) 2 (1) 2 (1)
5 I had enough opportunity to ask questions about the
EcLiPSE trial
134 (94) 7 (5) 2 (1)
6 I was satisfied with the deferred consent process for
the EcLiPSE trial
129 (90) 9 (6) 5 (4)
7 It was difficult to take in the information I was given
about the EcLiPSE trial
20 (14) 17 (12) 105 (73)
8 It was difficult to make a decision about the
EcLiPSE trial
15 (11) 15 (11) 112 (78)
9 I made this decision 122 (85) 14 (10) 7 (5)
10 Someone took this decision away from me 8 (6) 15 (11) 119 (83)
11 I was not in control of this decision 18 (13) 20 (14) 102 (71)
12 The decision about the research was inappropriately
influenced by others
8 (6) 15 (11) 115 (80)
a Totals may not equal 100% because of rounding.
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However, there was one exception. One mother (parent interview, mother, P11) described how she had
adequate capacity to make a decision about a trial when her child was being treated:
I was asking questions and stuff while she was having the seizure so it could’ve been mentioned to me
and I would’ve taken it in and I wouldn’t have questioned it after.
Parent interview, mother, P11
This mother described her sense of loss of control over the situation as ‘they’d done it without telling
us’. However, this parent felt able to consent for the use of her child’s data in the EcLiPSE trial as ‘they
use these two medications all the time’, which she found reassuring.
During trial discussions, parents often voiced their gratitude, thanking doctors and nurses for
conducting research into a condition that threatened their child’s life.
As shown in Table 14, despite parental satisfaction with the RWPC process, some parents (20/143,
14%) reported finding it difficult to take in study information at the point that they were approached
about the trial, whereas others (15/143, 10%) reported finding it difficult to make a decision. During
interviews, some parents described their child’s recent hospital episode as being ‘like a big blur’
(parent interview, mother, P1) because of the stressful situation.
Why parents agreed to the use of their child’s information in the EcLiPSE trial
During interviews, parents were asked for the reasons why they had provided consent for use of their
child’s data in the EcLiPSE trial. The questionnaire also included statements to identify the reasons why
parents had consented for their child’s information to be used in the trial. Parents commonly indicated
multiple reasons for providing consent. The majority (135/143, 94%) of parents indicated that a reason
they provided consent for the use of their child’s information in the trial was to help other children in
the future, whereas 46 (32%) parents indicated that this was their main reason.
In total, 124 out of 143 parents (87%) also indicated that they provided consent in the belief that
medical research, such as the EcLiPSE trial, is important, and 11 out of 94 (12%) parents indicated that
this was their main reason for giving consent. Interestingly, just under half of parents stated that they
had consented because their child had recovered. However, this was not a common reason described
during interviews, with only two parents mentioning that they were happy to participate in the trial
‘because it worked’ and one parent suggesting that ‘if it didn’t work then it might’ve been different’
(parent interview, mother, P24).
The nature of the trial interventions appeared to influence parental decision-making. Although parents
spoke of how it is ‘important that research happens’ (parent interview, mother, P28), many also stated
that they had found the EcLiPSE trial acceptable because they did not believe that the interventions
would harm or pose any risk to their child, as both were used in the treatment of seizures and were
likely to be effective in stopping a seizure:
It didn’t quite seem like a drastic choice anyway, two commonly used medicines. So it wasn’t like a risk at all.
Recorded trial discussion 27, parent
Others spoke of how their child may have benefited from involvement in the trial if the treatment had
been effective in stopping the seizure more quickly. In addition, some parents also acknowledged that,
as a result of the trial, there was potential for their child to benefit from evidence-based medicine in
the future:
Well I guess potentially if it happened again there might be benefit for [child’s name], and it may have
benefited her at the time . . . It might have stopped the fitting.
Parent interview, mother, P28
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Importantly, throughout interviews and during the EcLiPSE trial recruitment discussions, parents cited
their trust in practitioners as acting in the best interests of their child, with 89 out of 143 (62%)
questionnaire participants indicating that a reason they consented was ‘because I trust the doctor or
nurse who explained EcLiPSE’:
I was happy for them, as experts, to take it into their own hands and do what they felt was best for my
child, and for me to sit on the sidelines and just hope that everything was going to be OK.
Recorded trial discussion 70, parent
Finally, parents valued practitioners’ explanation of the trial, including the time they had taken out of
their clinical duties to explain it to them. Some described how they appreciated having an in-depth
conversation with a consultant about the trial and how clear explanations helped them in making their
decision on consent:
They just made the effort to ring and talk about it, so can’t remember her name either, but she was
incredible. She just took me through everything very slowly and explained everything.
Parent interview, mother, P6
Parental awareness and responses to the EcLiPSE trial at the point of randomisation
During SIVs, practitioners frequently asked the trial team how best to respond to parents who noticed
the trial randomisation envelope being opened during resuscitation. In the site training evaluation
questionnaire, fewer than half (60/125, 48%) of practitioners responded positively to the statement
‘I feel confident in dealing with parents who object to their child being randomised’. Prior experience
of RWPC was not associated with increased confidence in dealing with parents’ objections at the point
of randomisation (p = 0.288). Practitioners were concerned that parents would have questions that
would lead to discussions that would potentially delay the administration of time-critical treatments.
Practitioners were also worried that parents might object to or be upset about RWPC, creating friction
in an already highly emotive situation:
You’re like oh my God, what are they [parent] going to say, what are they going to do.
Practitioner telephone interview, female, lead research nurse, P8
Specific training was developed to help address such concerns, including how to respond to parents
who asked about the study at the point of randomisation, and to direct parents to posters and leaflets
in the ED if further information was requested.
Parents were asked during interviews about the first time that they had heard about the trial and
explored their knowledge of trial processes taking place during resuscitation. The majority of parents
stated that they ‘didn’t know anything about the study at that point’ (parent interview, mother, P1).
This view was echoed by practitioners who stated that, in most cases, ‘I don’t think they specifically
asked the question [about the study]’ (focus group 6, male, doctor, P1). Doctors and nurses who had
randomised patients stated how the process worked well and without the anticipated problems. This
was attributed to how ‘parents are focussed on their child’ and the opening of a randomisation
envelope not being ‘explicitly done in front of them’ (focus group 5, female, doctor, P1).
A few parents stated that they had noticed trial posters in the ED but had not given them any further
consideration because of the emergency situation. Nevertheless, some parents, particularly those with
previous experience of their child being admitted to hospital with tonic–clonic seizures, did notice the
randomisation envelope. In these cases, a brief discussion about the trial, including what drug had been
allocated, appeared to make parents feel that practitioners ‘were keeping me involved’ (parent interview,
mother, P15) and prevented concerns or negative responses during resuscitation. Practitioners described
how the provision of brief information about the EcLiPSE trial when parents noticed the opening of
an envelope, or ‘something different’ was happening, was important to maintain parental trust by being
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‘really transparent’ (focus group 2, female, nurse, participant 6). However, when no questions were
asked, it was not always possible for practitioners to know whether or not parents had noticed trial
processes were taking place. As the below quotation from a recorded trial discussion shows, one parent
had noticed the randomisation process, had not asked questions and had not noticed any the EcLiPSE
trial information in the ED. This lack of knowledge about what was going on made this father feel
uncomfortable and suspicious that something ‘dodgy’ was going on:
I’m like what’s all this whispering about? What’s the dodgy envelope? My kid is unconscious; tell me what’s
going on. So it definitely made me uncomfortable. I don’t have the answer but yes, I definitely felt that.
Recorded trial discussion 52, parent
How information about the trial was exchanged during discussions on recruitment into the
EcLiPSE trial
Previous studies have shown that how a clinical trial is explained is a key determinant of recruitment
and how patients experience and understand a trial.57–59 To the best of our knowledge, there are no
published reports on how practitioners explained to parents that their child had been included in a trial
in the ED, and whether or not they understood this explanation. Nineteen matched recorded trial
discussions and parent interviews were analysed to explore how EcLiPSE trial information, including
discussion of RWPC, was exchanged between practitioners and parents. This included exploring
questions parents had about the trial and how they were addressed, as well as how parents recalled
and understood aspects of the study when questioned during interviews approximately 1 month later.
We also drew on wider data (i.e. 76 recorded trial discussions and 30 parent interviews) to corroborate
our findings.
Our analysis was informed by the Realpe et al.57 six-step model, which provides a framework for
successful recruitment to RCTs. The model steps are (1) explain the condition, (2) reassure patients
about receiving treatment, (3) establish uncertainty, (4) explain the study purpose, (5) give a balanced
view of treatments and (6) explain study procedures (see Appendix 10, Figure 11). There are also two
elements used throughout the trial discussion: (1) responding to patients’ concerns and (2) showing
confidence and a relaxed manner. Owing to the nature of the audio-recorded data, we were unable to
fully assess whether or not the practitioners showed confidence and a relaxed manner.
Discussion of trial information and parental understanding
The sequence of how trial information was presented by EcLiPSE trial practitioners differed to the
Realpe et al.57 six-step model (see Appendix 10, Figure 13). This difference reflects the RWPC approach,
as well as parents’ prior knowledge of their child’s condition, which meant that a discussion of seizures
(i.e. step 1 in Realpe et al.’s57 model) was often not part of the trial discussion.
We found that parental understanding of the EcLiPSE trial was enhanced when practitioners provided
a comprehensive description of trial aims; explained the reasons for RWPC; discussed uncertainty
about which intervention was best; provided a balanced description of trial intervention; provided a
clear explanation about randomisation; and provided an opportunity for questions. Interestingly, this
common sequence of information provision did not match the order in the participant information
sheets, suggesting that practitioners had tailored verbal information for parents and had not simply
read out the information sheet (see Appendix 10, Figure 14 for a new seven-step model to optimise
recruitment in future trials that involve RWPC).
How checking understanding and providing opportunities for questions led to
patient-centred trial discussions
In the majority of conversations about recruitment, practitioners checked parental understanding and
provided opportunities for them to ask questions, and 38 out of 76 (50%) parents asked questions
during these discussions. Previous experience of their child having a seizure did not appear to have an
impact on whether or not parents asked questions.
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Practitioners tailored discussions to specific parental questions. This meant that, although the six steps
were often covered in discussions, practitioners would not strictly follow the sequence or they would
revisit certain steps (e.g. description of treatments) to provide additional information. Questions
typically focused on treatment information, such as which drug their child received, and the safety,
effectiveness and side effects.
Parents spoke of how their questions about the trial had been sufficiently addressed during the
trial discussion:
The doctor explained everything and he was really good.
Parent interview, mother, P1
Parental understanding of the EcLiPSE trial was influenced by the level of verbal
information provided
Analysis of recorded trial discussions indicated that most practitioners clearly described the trial’s aims
and objectives. Initial descriptions of the trial focused on its size, including the number of hospitals
involved, the trial interventions, the trial’s aims and why the child was eligible and had been recruited.
Consequently, during interviews, most parents were able provide a reasonably clear description of the
aims of the trial:
Basically that there’s two medicines that they can give that they know stops seizures but they didn’t know
which was the best one or the preferred one to use and that’s why you’re doing this study, to see how it
affects different people.
Parent interview, mother, P15
Practitioners sometimes described an equivalence, ‘The study is looking at is it [Keppra] as effective as
phenytoin’ (recorded trial discussion 27, practitioner), rather than a superiority hypotheses, ‘Whether
actually is Keppra more efficient at stopping a seizure more quickly than phenytoin’ (recorded trial
discussion 4). This seemed to influence parents’ understanding of the trial design and is not necessarily
surprising, as a fairly technical understanding would be needed to understand clinical trials methodology.
Matched audio-recorded discussions and interview analysis showed that more detailed trial
discussions, covering all six steps, led to improved parental understanding and retained information.
For example, when some parents were asked to recall what they had understood about the trial during
the recruitment conversation, as well as to the researcher in an interview 1 month later, they were
able to clearly explain the differences in how the two interventions were used in hospital departments
and the rationale of the trial:
What I have understood is that you have been using this new drug for years, but what you still want to
know, is the drug still capable of working or is there another way you can control kids who have fits like
[child] has for such a long time, and without the research how are you going to know what is the best
thing for the kids without causing them too much distress than what they are already going through.
Recorded trial discussion 6, parent
What they explained was even though there were two drugs for children with epilepsy, to try and control
it, it did say one of the drugs had only just been recently used in A&E [accident and emergency]. He said
they had both been used for years, but one of them was kept out of A&E. Now he said they were
introducing it into A&E, and they just wanted to know which drug would be best suited to control
children with epilepsy.
Parent interview 3, matched with recorded trial discussion 6
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By contrast, practitioners who had brief discussions with parents, covering only limited aspects of the
trial, resulted in parents being unable to recall it in any detail when interviewed. For example, in one
very brief trial discussion (i.e. 3 minutes and 27 seconds in length) that covered the trial aims, the two
drugs involved and reassurance that their child received ‘the normal treatment she would normally
have anyway’ (recorded trial discussion 2, trial recruiter), the parent was subsequently unable to recall
any details of the conversation, including which drug her child had received:
I can’t remember any names of them.
Parent interview, mother, P4
Despite all parents in this sample being provided with, and confirming that they had read and
understood, a written information sheet, it was clear that verbal information provided during trial
discussions was prioritised, understood and recalled. Parents appeared to value the manner in which
information was delivered by practitioners. During interviews, parents often referred to how the trial
was ‘really well explained’ (parent interview, mother, P15) by doctors or nurses who were ‘sympathetic’
and ‘absolutely lovely’ (parent interview, mother, P13).
Descriptions and understanding of randomisation was assisted by the use of an envelope
Previous studies have shown that patients often struggle to understand trial processes, such as
randomisation,60 and may not believe that chance was involved in treatment allocation.61 Interestingly,
analysis of recorded trial discussions and interview data indicated that the majority of practitioners
had explained the EcLiPSE trial randomisation process clearly and parents had understood the process.
Practitioners often provided confident, yet simple, descriptions of randomisation. These explanations
may have been assisted by the tangible nature of the EcLiPSE trial randomisation process itself, which
involved the opening of a pre-filled envelope. However, there were some examples of when parents
were unable to recall details of the randomisation process, despite there being a description in the
parent information sheet. We found that in these examples practitioners had not explained this to
parents during trial discussions:
Do you know, I can’t but I just know I know what randomised selection and stuff means anyway.
I couldn’t really tell you how it was explained to me.
Parent interview, mother, P3 matched with recorded trial discussion 2
Parental capacity to understand trial information was influenced by previous experience of
child seizures
There were examples of practitioners giving a comprehensive explanation of the trial, yet parents
were unable to recall any of the conversation. This lack of recall was attributed to the highly emotive
situation and sleep deprivation. We found that parents of children who had experienced their first
seizure were often unable to recall the recruitment conversation or describe any key aspects of the
trial, including the trial drug administered to their child. This finding was also apparent in the subset of
parent interviews for which we had a matched recorded trial discussion. In these examples, their first
experience of their child having a seizure understandably had an impact on parental capacity, despite
recruitment conversations taking place after their child’s seizure had stopped and the life-threatening
situation had passed:
It was really traumatic. The only thing I can remember is going in where the ambulance took us and there
were loads and loads of doctors around getting nurses and stuff and she was just lying on the bed. Then
they came in and said, I can’t remember, but I later remembered the first thing is that they said they have
an envelope and they opened the envelope.
Parent interview, mother, P4
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In addition, a few parents continued to be distressed and upset when their child had fully recovered
from their seizure and lacked the capacity at the time to understand the recruitment conversation:
I do remember the consultant kept saying to me, are you OK, do you understand what was just . . . and I
was just crying the whole time I think.
Parent interview, mother, P18
By contrast, parents of children who had previously been admitted to hospital with a tonic–clonic
seizure were often able to provide detailed and accurate descriptions of the trial, such as the trial aims,
treatment interventions and why informed consent could not be sought in the emergency situation:
Basically that you were doing which medicine, either Keppra or phenytoin, worked best for stopping
seizures . . . It wasn’t really putting her in any danger because it’s what they use anyway for children.
Parent interview, mother, P11
The impact of an unblinded trial design
Parental knowledge of intervention allocation
As the EcLiPSE trial was unblinded, trial recruiters commonly informed parents about which trial
intervention their child had received. In total, 23 out of 30 (77%) parents interviewed recalled which
drug their child had received. One parent stated that both drugs had been given to their child, but was
unsure which one was the trial intervention. Six out of 30 (20%) parents could not recall which drug
their child had received, but this did not appear to concern parents because their child had recovered:
Gosh, I don’t know. Basically we were just glad he got through it. I didn’t really care what he was given.
Parent interview, mother, P6
Equipoise and uncertainty about which drug is best
A few of the staff interviewed in focus groups at the end of the first year of the trial described how
they had presented the intervention allocation in a positive light to parents, regardless of which drug
the child had received:
So they’ve either had the, you’ve got the standard drug, great news. Or, you’ve got the new wonder drug,
great news.
Focus group 6, male, doctor, P1
Analysis of the first 34 recorded trial discussions that were received indicated that seven practitioners
(21%) favoured the allocated intervention. Most practitioners (6/7, 86%) spoke more positively about
levetiracetam and did not describe the uncertainty about whether or not it is more effective at
stopping long-lasting seizures than phenytoin. This positive presentation of one intervention
is likely to result from the unblinded trial design, lack of equipoise and perhaps practitioners
wishing to reassure parents that their child’s safety had not been compromised by participation
in the trial.
As part of the iterative design, the consent team added a section to the November 2016 EcLiPSE trial
newsletter for sites, which highlighted the importance of providing a balanced description of both
trial interventions. Analysis of the recorded discussions that took place after the newsletter had been
distributed indicated that this simple intervention was effective because subsequent discussions were
equipoised. In total, only 7 out of the 76 (9%) recorded trial discussions were not in equipoise
following the newsletter. Overall, trial practitioners provided parents with a brief but balanced
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description of the two interventions. Importantly, when practitioners described uncertainty as to which
drug was better during discussions, parents often provided very similar descriptions of the uncertainly
of effectiveness during an interview:
There are these two drugs and one of them – we have used both of them for a long time but we have
only used one of them in the emergency setting but we are wondering whether the other one might work
well, better or worse. That is what we are trying to find out.
Recorded trial discussion 6, trial recruiter
What they explained was even though there were two drugs for children with epilepsy, to try and control
it, it did say one of the drugs had only just been recently used in A&E [accident and emergency]. He said
they had both been used for years, but one of them was kept out of A&E. Now he said they were
introducing it into A&E, and they just wanted to know which drug would be best suited to control
children with epilepsy.
Parent interview, mother, P3, matched with recorded trial discussion 6
Successfully conducting an emergency department-led paediatric trial
During telephone interviews and focus groups, the researcher sought practitioners’ views on
perceived barriers to and facilitators of conducting an ED-led trial. The EcLiPSE TMG was particularly
interested in what facilitated or hindered ‘buy-in’ at the participating sites, with ‘buy-in’ being defined
as when all those involved in trial conduct are supportive of the trial and working to ensure that the
trial is a success.
Motivation and leadership
In addition to the training issues described above, motivation and leadership within and across sites
were identified as important factors in the successful conduct of the EcLiPSE trial.
Lead research nurses or principal investigators commonly described their enthusiasm for taking part
in the study from the very early stages of the trial. This enthusiasm was evident, despite some initial
concerns about training staff for the trial. Site leads acted as advocates for the study, raising
awareness and ensuring that all relevant staff were trained in delivering the protocol:
I think that we had taken on the study so we were very keen to do it. So myself as the lead and the
research nurses, so even though we internally had our concerns, we were very strong at promoting
it after we had that initial site visit. In our education with all the juniors, we very strongly advocated it.
Practitioner telephone interview, female, doctor, P3
A strong motivated leader, such as the principal investigator or lead research nurse, was seen as
important to engage staff and ensure that eligible patients were not missed. Practitioners emphasised
the importance of principal investigators taking responsibility for promoting the trial. This included
making time to disseminate training and motivating the wider team to take ownership in recruiting
patients 24 hours per day, 7 days per week. This was often challenging in busy EDs. Strong leadership
was not evident at a few sites, which had a negative impact on staff engagement and ultimately the
number of patients recruited at these hospitals. This was rare but highlighted the importance of
identifying a motivated and committed principal investigator throughout the trial:
There were three consultants and then there were two ANPs [advanced nurse practitioners], and they’re
just not interested. It’s not just this study, we’ve had it with a couple of others, there’s just a bit of a lack
of interest with research . . . So I think nobody is taking ownership really.
Practitioner telephone interview, female, lead research nurse, P1
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The importance of a clinically relevant research question and simple trial design
Practitioners described how the EcLiPSE trial research question was important and clinically relevant,
which was a crucial factor in engendering interest and ‘buy-in’ from the site teams, as well as support
from parents who also wanted evidence-based treatments for their child:
It’s a really important question that people want answered, and I think that’s one of the reasons . . .
I think for parents it’s something that they want. They want answers. If you’ve got a child in status,
I want the best drug which I think is different to some of the other studies that are around.
Focus group 4, female, doctor, P2
Many ED practitioners cited the value of the simple and pragmatic trial design, which meant that the
protocol was easy to follow in an emergency situation. It also facilitated engagement with the trial.
During focus groups, they spoke of the benefits of having a trial protocol that aligned very closely to
their usual practice and did not involve much additional work and documentation:
The great thing about EcLiPSE we have had was the pragmatism was just really primary for practice and,
unlike commercial studies that I’ve been involved in where they try and bolt on a thousand and one extra
things for you to do.
Focus group 3, female, nurse, P3
Collective engagement through site initiation visits
During interviews, practitioners spoke of how the involvement of a number of the EcLiPSE trial team
members, including the chief investigator, in delivering the SIV training had helped to create a sense of
importance of the research question and the trial. It also helped engage practitioners. They also valued
the invitation that as many people could attend the SIV as possible so that the trial could be explained
and questions answered:
I think people were very impressed that the chief investigator had arrived . . . they saw that as a really,
really good sign that people were taking this very seriously.
Practitioner telephone interview, male, doctor, P2
Teamwork
Many spoke about how working together as a team, both with the central EcLiPSE trial team and at
the site, was important to assist engagement on site initiation and to facilitate recruitment:
Trial teams don’t generally come back and ask all these questions. We don’t usually get this much support.
Focus group 4, female, nurse, P3
Teleconferences involving all sites were viewed as a useful method of sharing good practice and
raising any concerns. Individual sites produced trial posters visible in their ED and developed their
own incentives to help maintain awareness of the trial to assist recruitment. These were agreed by
the central EcLiPSE trial team and, when appropriate, the Research Ethics Committee. Finally,
despite best efforts, a minority of sites described how they struggled to work as a team because
of insufficient research nurse support or lack of engagement by key staff:
I think not having [nurse] working in research, well that hasn’t helped . . . But even when he was working
with us, I don’t think we were necessarily always completing a log screen for every single case that came in.
Practitioner telephone interview, male, lead research nurse, P9
Discussion
Our findings show how interactive site training, developed using pre-trial research and RWPC
guidance, can significantly alleviate practitioner concerns about recruitment and consent in a
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challenging PEM trial. For many participating hospitals, the EcLiPSE trial was the first time that teams
worked together to ensure that critically ill children were randomised to a trial during resuscitation
without prior informed consent. Prior to site training, many practitioners expressed concerns about
conducting the trial and lacked confidence in how to communicate to parents some of its elements,
including RWPC. Practitioners rated highly the clarity and content of SIV training. Significant improvements
were observed in practitioners’ confidence in explaining the study, randomisation and RWPC to families,
as well as how to respond to parents who might object to their child being randomised during an
emergency resuscitation. Site training provided an opportunity to discuss and learn about the potential
challenges and solutions to trial recruitment and conduct.62,63 Our findings suggest that the use of
training videos significantly aided this process and helped practitioners to visualise potentially difficult
trial processes, including screening in a resuscitation situation. Practitioners particularly valued the
RWPC video, which had been informed by data on parents’ views and priorities from pre-trial research43
and CONNECT study guidance on RWPC.48,49 The video provided practitioners with examples of how to
communicate RWPC to parents,48,49 as well as preparing them for a range of questions parents might ask
about the trial.43
Recorded trial discussions and interviews conducted with parents and practitioners throughout the
EcLiPSE trial provided insights into how information about the trial and RWPC had been exchanged
and understood. Overall, trial practitioners provided parents with a brief but balanced description of
the two interventions to parents. Parental understanding of the trial was enhanced when practitioners
clearly described trial aims, the reason for RWPC, uncertainty about which intervention was better, a
balanced description of both interventions and the randomisation process, and welcomed questions.
We provide a bespoke seven-step framework to optimise PEM trial RWPC discussions. Further testing
of this framework in future PEM trials is required, as are parent and practitioners views and
experiences of RWPC.
Multiple factors, including trial design, logistics and leadership, were found to both challenge and
contribute to trial recruitment and conduct. Importantly, both parents and practitioners wanted to
know the answer to the research question, which appeared to underpin many of the decisions and
behaviours identified in our study. Our findings also suggest that practitioners were engaged and
invested in the EcLiPSE trial because of its pragmatic design, which aimed to answer an important
clinical question that they believed would quickly inform their daily practice. This engagement was
apparent across the majority of EcLiPSE trial sites, despite initial concerns about whether or not the
trial was possible, which was often confounded by inexperience of conducting an ED-led trial. Our
findings highlight the important role of researchers and funding panels when the clinical relevance of
the research questions and how challenging trials are more likely to succeed, if these are relevant and
important to all key stakeholders, including patients, family members and clinicians.64,65
As has been shown in recent pilot studies56,66 exploring treatments for paediatric suspected infection,
parents and practitioners found RWPC to be acceptable. They understood its principle of avoiding
unethical delays in the delivery of potentially life-saving treatments. Practitioner concerns that parents
would notice the randomisation envelope being opened in the ED and would object to the trial or
RWPC, or both, were mostly unfounded. Parents of children who had a prior diagnosis of epilepsy
seemed to be more likely to notice something different was occurring, such as the opening of the
randomisation envelope. These parents valued how practitioners provided them with brief description
of the study, including what drug had been allocated. As shown in other studies57,67,68 that have
explored trial recruitment and decision-making, patients and family members often prioritise verbal
over written information provision, while the highly stressful and time-critical ED context is likely to
impact on parental capacity and, indeed, desire to read even short written study information.47 Future
trials would benefit from considering how their study and RWPC could be briefly communicated to
parents of children who are regular ED attenders, if deemed appropriate.
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Strengths and limitations
Although most sites (87%) took part in the evaluation, only 47% of eligible practitioners anticipated
that they would be able to stay for the full consent training, and completed the questionnaires. Of these
practitioners, 16% were excluded from analysis because of incomplete questionnaires. This attrition was
because practitioners had to leave training early because of clinical commitments. However, our study
was strengthened by the conduct of interviews, focus groups and an online questionnaire with staff who
had, but also who had not, attended the SIV. This mixed-methods approach provided insight into multiple
perspectives to assist understanding of the longer-term uptake and impact of training on practitioner
confidence in recruitment and RWPC,50,51 and potential barriers to trial success. All sites participated in
the consent study and practitioners were purposively sampled for focus groups and interviews to ensure
sample variance (e.g. low- and high-recruiting sites). The majority of parents (75%) of children randomised
and treated in the EcLiPSE trial consented to participate in some aspect of the consent study and
qualitative recruitment stopped when data saturation was reached.55,69 However, none of the 19 (4.7%)
parents who declined their child’s involvement in the EcLiPSE trial consented to take part in the consent
study and, therefore, their views have not been able to be represented.
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Chapter 5 Discussion
Parts of this chapter have been reused from Lyttle et al.1 This is an Open Access article distributedin accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license,
which permits others to copy and redistribute the material in any medium or format, provided the
original work is properly cited. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
To the best of our knowledge, the EcLiPSE trial is the largest and most clinically pragmatic RCT to
compare levetiracetam with phenytoin in the treatment of paediatric CSE unresponsive to first-line
treatment. This trial, powered for superiority, did not detect a statistically significant difference in any
of the primary and secondary outcomes. The direction of effect favoured levetiracetam across the
primary outcome (i.e. time from randomisation to CSE cessation) and secondary outcomes (e.g. the
need for RSI and SARs), other than for the secondary outcome of admission to critical care, for which
the direction of effect favoured phenytoin. These findings were robust in all sensitivity analyses.
The results of the EcLiPSE trial were published in May 2019.1 A similar RCT, the Convulsive Status
Epilepticus Paediatric Trial (ConSEPT), which was undertaken in 13 EDs in New Zealand and Australia,
of 233 children aged 2 months to 16 years and used a similar protocol, including identical doses and
rates of administration of the two drugs, was published simultaneously in the same journal.41 The primary
outcome of the ConSEPT trial was clinical cessation of seizure activity 5 minutes after the completion of
infusion of the study drug, with levetiracetam infused over 5 minutes and phenytoin infused over 20 minutes.
Analysis was by intention to treat. Results showed that clinical cessation of seizure activity 5 minutes after
completion of infusion of the randomised drug occurred in 68 (60%) patients in the phenytoin group and
60 (50%) patients in the levetiracetam group (risk difference –9.2%, 95% CI –21.9% to 3.5%; p= 0.16).
The authors41 concluded that levetiracetam was not shown to be superior to phenytoin for the second-line
management of paediatric CSE.
More recently, the results of the Established Status Epilepticus Treatment Trial (ESETT) from the USA
showed no statistical significance difference in its primary outcome (i.e. cessation of status and
improvement in consciousness at 60 minutes without the use of additional antiseizure medication)
between levetiracetam (at a dose of 60 mg/kg), sodium valproate and fosphenytoin (a pro-drug of
phenytoin and at a dose of 20 mg/kg). The primary outcome was achieved in approximately 50% of
patients and the frequency of AEs was similar in the three drugs.70,71
Prior to the publication of the ConSEPT trial, reported CSE cessation rates for levetiracetam and
phenytoin were broadly similar to a number of previously reported observational retrospective,
and predominantly adult, studies.14,30,31 However, CSE cessation rates as high as 85–95% have been
reported, although these studies display significant heterogeneity in design and outcomes.72–74 A recent
prospective RCT74 of only 50 children recruited over a 6-month period reported that levetiracetam
(at a dose of 30 mg/kg) terminated CSE in 92% of children and fosphenytoin (at a dose of 20 mg/kg)
terminated CSE in 84% of children (p = 0.66).74 These rates are considerably higher than those found in
the EcLiPSE trial, ConSEPT trial41 and ESETT.70,71 This also applied to the time to terminate CSE from
the time of commencement of the infusion. Fosphenytoin terminated CSE earlier (2.5 ± 1.4 minutes)
than levetiracetam (3.3 ± 1.2 minutes; p = 0.03).74 The equivalent median times in the EcLiPSE trial,
from time of commencement of infusion, were 17.5 and 24.5 minutes for levetiracetam and phenytoin,
respectively, and in the ConSEPT trial these were 17 and 22 minutes, respectively. The methodology of
the study by Senthilkumar et al.74 was limited and each treatment group comprised only 25 patients
(this may explain their markedly discrepant findings with the EcLiPSE trial for both CSE cessation and
the speed with which this was achieved). Finally, although fosphenytoin can be administered more rapidly
than phenytoin, it can still not be administered as quickly as levetiracetam. Consequently, the findings of
Senthilkumar et al.74 remain difficult to understand and it is uncertain if they would be generalisable.
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One RCT,28 undertaken in adults with CSE, compared the efficacy of i.v. phenytoin (20 mg/kg), sodium
valproate (30 mg/kg) and levetiracetam (25 mg/kg) in 150 patients unresponsive to i.v. lorazepam. CSE
stopped in 34 (68%) patients treated with phenytoin, 34 (68%) patients treated with valproate and 39
(78%) patients treated with levetiracetam (p = 0.44). A paediatric RCT,72 published in 2018, evaluated
100 children aged 3–12 years receiving levetiracetam (30 mg/kg) or phenytoin (20 mg/kg) if CSE
continued after one dose of i.v. diazepam.72 Efficacy was high and almost identical in both groups. A
lower diastolic blood pressure was recorded in phenytoin-treated patients (p = 0.023). It is difficult to
translate these findings to clinical practice because of the trial’s design, including its many exclusion
criteria and its primary outcome,71 which was ‘absence of seizure activity within 24 hours’. This is an
unusual and very rarely used primary outcome in other studies of CSE. It is also not a practical and
‘real-life’ clinical goal, as the emphasis should be on the termination of the presenting seizure as soon
as possible after treatment has been given, and not the child’s condition after 24 hours. Consequently,
it would be difficult, and probably inappropriate, to use the same primary outcome in routine clinical
practice in the UK and elsewhere. Childhood CSE management in the UK follows the APLS algorithm,11
which is applicable to the vast majority of children presenting to an ED. Our study design used
eligibility criteria that were as inclusive as possible, and followed a well-recognised treatment pathway
that reflected routine clinical practice.
Children with focal and generalised CSE were included because their management is the same in the
APLS algorithm. In addition, it may be difficult to accurately distinguish focal and generalised
convulsive seizures in infants and children aged < 3 years.
We did not detect a statistically significant difference between levetiracetam and phenytoin in time to
CSE cessation. A superiority design was selected for three reasons: (1) the reported CSE cessation
rates for each drug, hypothesising that levetiracetam would be more effective; (2) the absence of any
RCT data comparing the effectiveness of either phenytoin or levetiracetam with placebo and (3) the
shorter infusion time of levetiracetam (i.e. 5 minutes vs. at least 20 minutes for phenytoin). We selected
time from randomisation, and instructed sites to undertake randomisation at the latest possible point
that would allow reconstitution of the allocated treatment to provide scientific and clinical rigour. As
the median time to commencement of infusion exceeded 10 minutes in each arm, we also undertook a
sensitivity analysis, using time to cessation of CSE from commencement of the infusion. This supported
our primary analysis findings and demonstrated that the median time from commencement of the
infusion was similar to the median time from randomisation in both treatment groups. This is interesting,
as it might have been expected that CSE would have been terminated more quickly with levetiracetam
(with infusion time of 5 minutes) than phenytoin (with infusion time of at least 20 minutes). One
explanation for this observation could be that the anticonvulsant effect of phenytoin may be achieved
prior to completion of its infusion. As far as we are aware, there is no literature that has specifically
evaluated how rapidly an infusion of phenytoin might terminate CSE once it has been commenced. The
ConSEPT trial41 also showed no significant difference between levetiracetam and phenytoin in time to
CSE-cessation.
Progression to RSI in CSE may be required for one or a combination of reasons, including continuing
CSE, respiratory depression, clinical deterioration and stability for transfer, or to safely undertake
investigations, specifically neuroimaging. However, RSI abolishes visible CSE activity and may, therefore,
prevent an assessment of CSE cessation directly related to trial treatment. Participants were, therefore,
censored at the time of RSI, but the censoring time was increased to allow for this to be a negative and
potentially informative outcome. This may have artificially inflated the time to CSE cessation. However,
sensitivity analyses that censored patients at the time of RSI, and defined RSI as a competing risk, did
not change our findings.
Safety profiles were similar across both treatments. Owing to their relative infrequency in relation to
the trial population size, together with good clinical management in participating sites, the trial showed
low rates of SARs. Only 4 out of 286 (1.4%) patients experienced a total of five SARs (three in the
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phenytoin-treated group and one in the levetiracetam-treated group) and in only one of these patients
was the reaction (i.e. marked hypotension) considered as being ‘probably’ related to the study medication
(phenytoin). One SAR occurred in a patient who received both anticonvulsants. One phenytoin-treated
patient experienced a SUSAR, which manifested as a large increase in seizure frequency and marked
sedation within 24 hours of receiving phenytoin. An equally good safety profile was also reported by
the ConSEPT trial team,41 with one death in the phenytoin group 27 days after randomisation because
of haemorrhagic encephalitis that was considered to be unrelated to the study drug. The authors reported
no other SAEs or SARs. The safety profile of the 255 children (aged 2–17 years) who participated in the
ESETT70,71 was also good. Two deaths occurred, one in the levetiracetam-treated group and one in the
sodium valproate-treated group. Life-threatening hypotension and cardiac arrhythmias were rare and
did not differ by treatment group in any age. The only significant safety outcome was seen in children
requiring intubation more frequently in the fosphenytoin-treated group, an observation that could not be
readily explained by the authors. The authors reported no other differences in safety outcomes.71
The good safety profile of both anticonvulsants is encouraging, particularly for phenytoin, in view of
its well-recognised serious potential adverse effects of hypotension, cardiac arrhythmias and severe
extravasation reactions, including the ‘purple glove syndrome’.15,16 Rarely, the arrhythmia may be fatal
caused by non-resuscitatable cardiac asystole.18 In the USA, fosphenytoin, a pro-drug of phenytoin,
replaced phenytoin as the preferred second-line management of CSE, primarily because of its slightly
faster rate of infusion but also because of its perceived better safety profile. However, it may also
cause SARs and this, together with its relative cost to phenytoin, has precluded its use in the UK.
The literature on the safety of levetiracetam is less extensive because of the comparative short period
that it has been used in the treatment of CSE. However, despite the fact that this period spans < 20 years,
in comparison with the 50 years with phenytoin, it is important to note that, to date, there have been no
reports of severe Stevens–Johnson syndrome, purple glove syndrome or fatal cardiac arrhythmias
associated with the use of i.v. levetiracetam.
In the EcLiPSE trial, levetiracetam was well tolerated at an infusion rate of 5 minutes and this was
more rapid than previously reported (i.e. 10–15 minutes).27,30,31 Agitation was the most commonly
reported AE in the levetiracetam-treated group, as reported previously.26 There were no new or
unexpected SARs with levetiracetam. Sedation, somnolence and dizziness are rare side effects in
adults, but these may in part reflect the prior use of benzodiazepines or craniotomy in these study
populations.20,74 Anxiety has also been reported in adults, but was not reported as an AE or AR in this
or other paediatric studies. It is possible that anxiety in the adult may equate to agitation in the child.
Clearly, in view of the fact that 90% of our study population was aged ≤ 10 years (and 41% aged
≤ 2 years), anxiety might be difficult, if not impossible, for them or their carers to describe, and instead
used the terms ‘agitated’ or ‘irritable’.
More participants in the levetiracetam-treated group required admission to critical care (either a
high-dependency unit or a PICU), but this did not reach statistical significance. This finding is difficult
to explain. It was not explained by the demography of the two treatment groups, ongoing CSE, the
need for RSI, additional anticonvulsants, or the frequency of AEs or AEs. Potential explanations could
include a different type or nature (e.g. more severe) of epilepsy in the levetiracetam-treated group or
that the attending clinicians had a lower threshold of transferring participants to critical care, as
levetiracetam was a relatively new anticonvulsant. There did not appear to be a difference in the two
treatment groups regarding the type of epilepsy or additional comorbid conditions, or the numbers
that were still on critical care 24 hours after randomisation following post hoc analysis.
Children who were already receiving levetiracetam and phenytoin as oral maintenance antiepileptic
drugs were included in the study because this reflects real life. In most emergency situations and, in
particular, in the absence of information from carers, children will be treated in accordance with the
APLS algorithm. In addition, a recognised cause of CSE in patients with epilepsy at all ages is poor
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adherence to antiepileptic medication and consequent low blood levels of the medication. The relatively
high proportion of children receiving levetiracetam was partly expected and reflects current clinical
practice and perception that this drug has a broad spectrum of action (in treating different seizure types)
and is safe. The very small number of children receiving phenytoin was also predictable, as it is perceived
as having a very narrow spectrum of action, numerous drug interactions, significant long-term side
effects and is difficult to monitor. We consider it unlikely that the inclusion of children on levetiracetam
and phenytoin significantly affected our findings. Theoretically, it might have been predicted that those
children already receiving levetiracetam would not have responded as well to i.v. levetiracetam or
have shown more adverse side effects, or both, although this was not reflected in the overall results.
However, the small number of patients receiving levetiracetam across both treatment arms precluded
any formal subgroup analysis.
The EcLiPSE trial is a unique trial for many reasons. First, to the best of our knowledge, it is the first
adequately powered RCT to compare the efficacy and safety of two anticonvulsants as second-line
treatments for CSE. Second, to the best of our knowledge, it is the first adequately powered RCT to
evaluate phenytoin as a second-line treatment for CSE, despite this drug’s position as the first-choice
second-line treatment for > 50 years. Third, the trial incorporated a nested consent study that
evaluated the process of RWPC in a PEM trial.43,44 Last, to the best of our knowledge, it was the first
multicentre RCT to be supported by and delivered across the then emerging PERUKI collaborative.37,38
This trial has a number of strengths. First, it evaluated a specific step (i.e. second-line treatment) in
a UK clinical algorithm for the management of childhood CSE.11 A similar trial75 that assessed the
first-line non-i.v. treatment of CSE in the same algorithm led to a change in national clinical practice.
Second, it demonstrated that RWPC is acceptable and successful, with 385 out of 404 (95%) randomised
participants providing consent. Likewise, in those who were randomised and treated, 286 out of 311
(92%) participants provided consent. RWPC is essential for the successful delivery of paediatric
emergency care trials. The high consent rate mirrors that found in a previous trial75 of first-line CSE
management (consent rate 97%) and a pilot RCT56 that compared fluid boluses in shock (consent rate
100%). Third, it was a pragmatic trial and recorded only key primary and secondary outcomes in the
resuscitation room. This approach, supported by focused data-collection materials and simple allocation
and enrolment methods, facilitated successful delivery of the study across all sites, as shown by the small
numbers of missed patients, high protocol adherence and accurate data capture for key outcomes.
Finally, the trial was conducted in EDs in secondary and tertiary institutions throughout PERUKI, thereby
facilitating dissemination and increasing generalisability of our findings.
This trial has some limitations. First, it was open label. A double-blind design was considered too
complex for most participating sites, in part because of the markedly different infusion rates of the
two drugs, and within the context of the life-threatening and time-critical nature of CSE. Second, the
number of participants in one arm of the trial fell below the sample size calculation requirement
(134 vs. 140), whereas in the other arm it surpassed requirements (152 vs. 140); however, the effect of
this on power is considered unimportant. Third, there was probably subjectivity in the assessment of
‘cessation of all signs of continuous, rhythmic clonic activity’ as the clinical event for our primary outcome,
rather than fixed time points to assess CSE cessation. Clearly, these three limitations may collectively
increase the risk of bias. However, continual assessment of a child’s condition reflects ‘real-life’ practice in
a dynamic situation, in which clinicians constantly evaluate and prepare for the next step in the treatment
algorithm. Site training included a simulated demonstration of the end point to ensure an understanding
of the key outcome measure for the trial. In the ConSEPT trial,41 the primary outcome assessment
(i.e. CSE cessation 5 minutes after completion of the randomised infusion) was video-recorded. This was
to explore possible observer bias owing to the unblinded nature of the study design. Recordings were
obtained for 84 (71%) participants in the levetiracetam-treated group and 71 (62%) participants in the
phenytoin-treated group. Although this might have been feasible in a research setting in a few sites, it
would not be easily applied to routine clinical practice. It would not have been feasible or pragmatic for
each participant to undergo a video-recording or an electroencephalogram (EEG) to determine CSE
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cessation time more precisely. It is not possible to state definitively and without EEG whether or not any
patients may have developed non-CSE following either treatment. However, treatment algorithms for
non-CSE generally follow the same flow as CSE, and there was no difference between treatment groups
in the number of additional anticonvulsants given after trial treatment. EEGs were not used to determine
or confirm seizure cessation in the ConSEPT trial41 or ESTT.70,71 Third, the time point of randomisation
resulted in CSE terminating prior to administration of trial treatment in a number of cases; however,
this affected both treatment arms equally, and was essential to maintain high standards of clinical care
and avoid treatment delays. Fourth, we included safety measures as key secondary outcomes because
of previous reports of harm. However, this trial was not powered to demonstrate difference in SARs
(a secondary outcome) between treatment groups, given their low incidence rate. Finally, we considered
a superiority design was more appropriate for reasons given above.
Added value of this study
This is an adequately powered RCT that pragmatically and directly compares two anticonvulsants in
the second-line treatment of paediatric CSE in an emergency setting. It is also, to the best of our
knowledge, the first scientifically-robust clinical trial to compare the efficacy and safety of levetiracetam
with phenytoin in this common paediatric neurological emergency. We found no significant differences
between the two anticonvulsants in any primary or secondary outcomes, including time to seizure
cessation, need for additional anticonvulsants and progression to RSI. The safety profile was similar
between both treatments (note that this is in contrast to existing observational evidence that phenytoin
appears to have a worse safety profile, including causing a potentially fatal cardiac arrhythmia).
The study comprised a number of challenges, but also opportunities, that might have adversely
affected recruitment, including research within a paediatric emergency situation that involved RWPC,
which was a new concept to many participating centres. Early input from parents was obtained
through pre-trial feasibility43 and CONNECT guidance,46–48 which informed site training to maximise
recruitment into the EcLiPSE trial. The nested consent study provides valuable insight from parents
and practitioners to inform the design and conduct of future trials in this setting, including a bespoke
seven-step framework to optimise PEM trial recruitment discussions. Multiple factors, including trial
design, organisation and leadership, were found to both challenge and contribute to trial recruitment
and conduct. Early engagement with PERUKI optimised success of the trial through collaboration with
clinicians and researchers in the development and delivery of the study, together with the selection of
the most appropriate sites in which to recruit patients.
Implications of all the available evidence
The results of the EcLiPSE trial indicate that levetiracetam could be considered as an alternative
treatment to phenytoin for the second-line management of paediatric CSE. Recently published RCT
data from the ConSEPT trial41 and ESTT70,71 seem to confirm our results and our conclusion.
Additional treatment-related factors may be important to consider and are likely to be relevant to the
wider interpretation of our findings. First, levetiracetam is widely used as oral maintenance therapy for
many childhood epilepsies because of its broad-spectrum activity and safety profile; this was clearly
reflected in the EcLiPSE trial, with levetiracetam being the most commonly used oral antiepileptic drug
in all participants on presentation to the ED. By contrast, phenytoin is a rarely used maintenance
antiepileptic drug because of its complex pharmacokinetics and potential toxicity. However, despite its
rare use, anecdotally, many ED clinicians are reluctant to give a loading dose of phenytoin in CSE to
children on oral maintenance phenytoin because of the risk of potential overdosing and the risk of
potential cardiovascular toxicity, including a fatal arrhythmia. There seemed to be no similar concerns
for levetiracetam, and there was no observed increase in AEs following the i.v. administration of a dose
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of 40 mg/kg to children already receiving maintenance levetiracetam. In addition, in the levetiracetam-
treated participants, blood levels of the drug showed no obvious difference between those who were
and were not receiving it as a maintenance oral antiepileptic drug on presentation. Second, a significant
minority of children who present in CSE for the first time will be commenced on maintenance therapy
prior to discharge. This is more likely to be with levetiracetam than phenytoin because of the latter’s
adverse safety profile and unreliable pharmacokinetics. One observational study in adults showed that
8% of patients treated with i.v. fosphenytoin for CSE were subsequently commenced on oral phenytoin,
compared with 78% of patients treated with i.v. levetiracetam who were subsequently commenced on
oral levetiracetam.72 Third, ease of drug preparation and administration is also important in the
management of CSE.
Throughout the EcLiPSE trial, levetiracetam was reported by all clinical teams to be easier to prepare
and administer than phenytoin because of the latter’s calculations performed in reconstituting the
drug, the number of vials required and procedures needed for its administration (these observations
are supported by the literature20,74).
The majority of participants in the EcLiPSE trial were managed in accordance with the national APLS
algorithm, unless the clinical team considered otherwise. For children in whom the second-line
anticonvulsant fails to terminate CSE, RSI with thiopentone or another agent is the next step in the
algorithm. However, treatment strategies in the management of CSE are evolving. This includes the
emerging use of two, rarely three, second-line anticonvulsants in preference to the traditional practice
of immediate progression to RSI after failure of the first second-line drug. Clinicians might consider
the risks of RSI, and its potential iatrogenic consequences, to be greater than the administration and
assessment of a second second-line treatment. In total, 24 out of the 286 participants (8.4%) in the
EcLiPSE trial received both treatments sequentially (17 of these were randomised to, and received,
levetiracetam first). This could reflect the acceptance of a second second-line treatment being
conditional on the amount of time elapsed since CSE-onset.
In the ConSEPT trial,41 if CSE continued following administration of the randomised drug then the
alternative drug was given, with further assessment of seizure activity performed 5 minutes after the
infusion of the second trial drug was completed. Persisting CSE after the administration of both drugs
was subsequently managed by local protocols, all of which advised RSI and intubation. Consequently,
42 participants received phenytoin followed by levetiracetam and 48 participants received levetiracetam
followed by phenytoin. Clinical cessation of seizure activity at 2 hours following the administration of
the randomised drug only was seen in 62 (54%) participants in the phenytoin-treated group and 61
(51%) participants in the levetiracetam-treated group. However, seizure cessation at 2 hours having
received one or both study drugs increased this to 89 (78%) participants in the phenytoin-treated group
and 86 (72%) participants in the levetiracetam-treated group. The authors41 concluded that although
both drugs failed to terminate CSE in a significant number of patients when given alone, treatment
with one drug and followed by the other reduced the failure rate by > 50% at the expense of only an
additional 10 minutes (compared with giving phenytoin alone). The authors41 argued that clinicians
should, therefore, consider the sequential use of either medication first, before progressing to RSI and
intubation. It is understandable that clinicians might consider the risks of RSI and intubation to be
greater than the risks of administration and assessment of an additional second-line treatment.
However, the administration of two second-line treatments might substantially delay the use of RSI.
The ConSEPT trial team suggest that any delay would be < 10 minutes.41 However, in practice, the
preparation and administration of levetiracetam is likely to take > 10 minutes and closer to 15 minutes
and phenytoin is likely to take closer to 20 or 25 minutes because of its more complicated preparation.
Such a delay would significantly add to the overall period of CSE since its onset and would increase the
potential risk of neurological and cognitive impairment.
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Chapter 6 Conclusions
To the best of our knowledge, this was the first adequately powered RCT that has directly comparedany anticonvulsant in the second-line treatment of paediatric CSE in an emergency setting.
There was no statistical difference between the two anticonvulsants in any primary or secondary
outcome. Although the safety profile in the EcLiPSE trial was similar between the two treatments,
observational evidence over the past 50 years has indicated that phenytoin may be associated with a
worse safety profile, including death caused by cardiac arrhythmias and Stevens–Johnson syndrome.
Clearly, the observational data for levetiracetam are small and span approximately 20 years, but no
deaths from any cause attributed to this anticonvulsant have been reported during this period.
The results of the EcLiPSE trial suggest that levetiracetam may be considered as an alternative first-
choice treatment to phenytoin in the second-line management of paediatric CSE. Additional benefits
for levetiracetam compared with phenytoin are its ease of preparation and administration. Recent
results from two additional RCTs,41,70,71 in a total of 617 children and adults, would support its potential
first-choice position in the second-line management in children with benzodiazepine-resistant CSE.
The possible sequential use of phenytoin followed by levetiracetam, or levetiracetam followed by
phenytoin, is important; however, it requires debate and ideally by a multispecialty group that would
include PEM, paediatric neurology, paediatric intensive care and general paediatrics.
The EcLiPSE trial has provided new and robust evidence that, together with other recently published
RCT data,41,70,71 will help to inform clinicians in their management of paediatric CSE. This evidence will
also be assessed by National Institute for Health and Care Excellence in its revised epilepsy guideline
that is due to be published in 2022.
Finally, the nested consent study has provided valuable insight into factors that have helped to
facilitate the successful conduct of, and recruitment to, a challenging ED-led trial. These factors are
relevant for both the families of the trial participants and the practitioners who conducted the trial.
Its results will hopefully facilitate future research in paediatric EDs.
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Appendix 3 Recruiting centres in centre
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Participating trust Investigator
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Dr Andy Appelboam, Consultant EM (co-PI)
Su Wilkins, Clinical RN
South Tees Hospitals NHS Foundation Trust Dr Ramesh Kumar, Consultant Paediatrician (PI)
Dr Alex Scott, Consultant EM (co-investigator)
Cambridge University Hospitals NHS Foundation Trust Dr Matthew Pereira, Consultant EM (PI)
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Participating trust Investigator
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Participating trust Investigator
Brighton and Sussex University Hospitals NHS Trust Dr Catherine Bevan, Paediatric Consultant (PI)
Rebecca Ramsay, Senior RN
Great North Children’s Hospital Dr Mark Anderson, Consultant Paediatrician (PI)
Kirsty Devine, Paediatric RN
Wirral University Teaching Hospital NHS Foundation Trust Dr Mark Buchanan, Consultant EM (PI)
Sharon Hughes, RN
Chelsea and Westminster Healthcare NHS Foundation Trust Dr James Ross, Consultant PEM (PI)
Dr Jo Hacking, Consultant PEM (previous PI)
Dr Sara Edwards, Senior Registrar PEM (previous PI)
Natasha Ramsay, Paediatric Nurse Practitioner
Leeds General Infirmary Dr Alice Downes, Consultant PEM (PI)
Dr Helen Mollard, Consultant EM (previous PI)
Nicola Balatoni, Research Sister
AED, anti-epileptic drug; EM, emergency medicine; PI, principal investigator; RN, research nurse.
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Appendix 4 Changes to the protocol
Summary of amendments from protocol v1.0 (13 January 2015) to protocol v2.0
(23 April 2015)
Protocol section Summary of changes
Protocol summary l Study participation increased from 24 hours to 14 days. Follow-up
at 14 days for safety only
l Schematic of study design: updated to align with new follow-up
and change to inclusion criteria number 3
Primary end point l Defined as time to cessation of all visible signs of convulsive
seizure activity, will be calculated from the time of
randomisation. A secondary analysis will use time from the start
of the infusion
Internal pilot l Clarified that the internal pilot will involve five centres, but
other centres may also open during this period
Inclusion criteria l Inclusion criterion 2: definitions of presenting seizures have
been clarified
l Inclusion criterion 3: amended to ‘First-line treatment
administered according to APLS guidelines or the child’s
personalised rescue care plan to try and terminate the
presenting seizure’
l Eligibility notes: amended to align with the changes to the
inclusion criteria and clarify the definitions of first-line treatment
Exclusion criteria l Exclusion criterion 3: amended to align with updated inclusion
criterion 3
l Exclusion criterion 6: amended to ‘Known to have previously
been treated as part of EcLiPSE’
Screening l Process for assessing eligibility clarified
l Screening will now commence once a child has arrived in the ED
and has started first-line treatment. Reference to two doses of
benzodiazepines removed
Randomisation l Change to randomisation envelopes used. Randomisation packs
will instead include CRFs that are prepopulated with the
randomisation number and treatment allocation
l Process for patients who are randomised but not treated with
second-line treatment while in the ED defined
Patients randomised but not treated with a
second-line treatment in the ED
l Process for obtaining consent for patients randomised but not
administered a second-line treatment defined
Trial treatments introduction l Guidance on ‘actual’ weight removed
Preparation, dosage and administration of
levetiracetam
l Following sentence removed to ensure clarity on the dilution of
levetiracetam: ‘Levetiracetam should be diluted in accordance
with the manufacturers SmPC’
Accountability procedures for study treatments l Updated to align with new randomisation packs (see section 6.3)
Assessment of compliance with study
treatments
l Updated to align with new randomisation packs (see section 6.3)
Co-enrolment guidelines l Updated to include ‘should co-enrolment issues arise, patients
are permitted to enter EcLiPSE while participating in another
trial. This is providing that the other trial will not impact the
EcLiPSE primary end point. Any queries regarding co-enrolment
should be discussed with the CTU who will contact the
chief investigator’
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Protocol section Summary of changes
Schedule for follow-up l New follow-up period defined to include:
¢ follow-up for patients not administered a second-line treatment
¢ 14-day safety follow-up
Trial assessments l Follow-up time points clarified
l Height assessment removed
l Heart rate, oxygen saturation, respiratory rate and blood
pressure assessment removed
l 14-day safety follow-up added
Seizure activity l Seizure follow-up clarified as ‘24 hours after the second-line
infusion was started’
Procedures for assessing safety l Clarified AEs to be recorded from randomisation to 24 hours
after second-line infusion started
l Process for 14-day safety follow-up added:
¢ 14-day follow-up questionnaire
¢ 14-day hospital follow-up
Blood samples l Blood sample to be taken updated to ‘between 1.5 mls and 2mls’
Consent study l Table inserted to clarify when each section of the consent study
is applicable
Part A: audio-recordings l Transcriptions to be completed by ‘VoiceScript’ website
Sample size estimate l Updated to include ‘Due to deferred consent process this will
require 308 randomised patients for whom consent has been
sought and randomised treatment received’
Notes on AE recording timelines l Updated to align with changes to follow-up as per section 8.3
Flow chart for reporting requirements of AEs l Updated to align with changes to follow-up as per section 8.3
Reporting of overdose l Overdose classified as > 20% of the recommended dose
CRFs l Updated as per new randomisation process
l Reference to two-part, no carbon copy removed
N/A l Other minor typographical errors corrections and clarifications
to ensure consistency made throughout
CTU, Clinical Trials Unit; N/A, not applicable; SmPC, Summary of Product Characteristics.
Summary of amendments from protocol v2.0 (23 April 2015) to protocol v3.0
(17 June 2015)
Protocol section Summary of changes
Trial treatments introduction l Concentration of levetiracetam updated to a maximum of 50mg/ml
with sodium chloride 0.9%
l Concentration of phenytoin updated to a maximum of 10 mg/ml
with sodium chloride 0.9%
Preparation, dosage and administration
of levetiracetam
l Concentration of levetiracetam updated to a maximum of 50mg/ml
with sodium chloride 0.9%
Preparation, dosage and administration
of phenytoin
l Concentration of phenytoin updated to a maximum of 10 mg/ml
with sodium chloride 0.9%
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Summary of amendments from protocol v3.0 (17 June 2015) to protocol v4.0
(27 august 2015)
Protocol section Summary of changes
N/A l Additional reference numbers inserted
Protocol summary: schematic study design l Maximum dose and infusion times for phenytoin updated
Trial treatments introduction l Maximum dose of phenytoin increased to 2000mg
l Infusion times for phenytoin updated:
¢ Infusion time for dose ≤ 1000mg: over 20 minutes
¢ Infusion time for dose > 1000mg and ≤ 1500mg: between
20 and 30 minutes
¢ Infusion time for dose > 1500mg and ≤ 2000mg: between
30 and 40 minutes
Preparation, dosage and administration
of levetiracetam
l Reference to the New Zealand guidelines updated
Preparation, dosage and administration
of phenytoin
l Updated to confirm that the ‘total maximum dose of phenytoin
administered should be 2000mg. However, sites should confirm
prior to study start if their local procedure states that the
maximum phenytoin dose is less than 2000 mg. If this is the
case then maximum dose for phenytoin should be as per local
procedure and should be adhered to’
l Infusion times for phenytoin updated
Part B: parent/legal representative
questionnaires
l Updated to confirm online version of the questionnaire can
be completed
l Clarified that if more than one parent/legal representative is
involved in the consent discussion, both can complete
a questionnaire
l Updated to confirm that the consent study team may follow-up
for missing questionnaires when completing consent follow-up,
if consent has been obtained for this
Part C: interviews l Updated to allow face-to-face interviews for parents/legal
representatives who live in (or close to) the Merseyside area if
this preferred
N/A l Other minor typographical errors corrections and clarifications
to ensure consistency made throughout
N/A, not applicable.
Summary of amendments from protocol v4.0 (27 August 2015) to protocol v5.0
(5 April 2017)
Protocol section Summary of changes
Contact details l Contact details updated for CTRC, Richard Appleton and Anand Iyer
Protocol summary l Contractual title with the HTA programme added
Randomisation l Updated to confirm that ‘Once randomised, the patient should
be administered the randomly allocated treatment when
required clinically to terminate seizure activity. If seizure
activity has ceased or the patient has been given a RSI prior to
administration of any second-line treatment then the decision to
administer a second-line treatment is outside the EcLiPSE trial
the patient should be treated as per standard care. Follow-up
will be as detailed in section 8.1 and consent should be sought as
per section 6.4.11’
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Protocol section Summary of changes
Consent/assent form completion l Clarification on where original consent forms should be filed if
the trust has moved to electronic medical records
Definitions of legal representatives l Definitions updated to include Northern Ireland and
Scottish minors
Death prior to deferred consent being sought l Allowable window added for sending information via post to
bereaved families
Discharge/transfer prior to deferred consent
being sought
l Time window added for when information should be sent to the
families once the telephone call has been completed
l 14-day follow-up questionnaire added as a document to be sent
to families when following the consent from home process
Patients randomised but not treated with
second-line treatment in the ED or second-line
treatment administered after RSI/seizure
stop time
l Confirmation that patients administered RSI or seizure stopped prior
to second-line treatment should follow the not-treated pathway
l Questionnaire for not-treated participants added
l Confirmation that those participants consented as not treated
are not included in the recruitment figures for the study, as they
were not administered second-line treatment as per the
APLS protocol
Deferred consent declined l Consent tracking form will confirm that the patient has declined
consent and which (if any) second-line treatment was administered
Participant transfers l Confirmation that if a patient is transferred to another EcLiPSE
trial recruiting site then the transferred site can assist with the
consent of the patient
Trial treatments: introduction l Clarification on the route of administration. The following text
inserted: ‘At the time of randomisation if it is clear that the trial
treatment needs to be administered via the intraosseous route
then the patient should not be randomised. If this becomes the
case after the patient has been randomised then this should be
documented appropriately on the CRFs and all follow-up
data collected’
Arm A: levetiracetam – formulation l Confirmation of the SmPC used for levetiracetam reference
safety information
l Clarification that sites will no longer be provided with example
SmPCs and instead should use the current SmPC available from
the eMC website or equivalent
Arm B: phenytoin – formulation l Confirmation of the SmPC used for phenytoin reference
safety information
l Clarification that sites will no longer be provided with example
SmPCs and instead should use the current SmPC available from
the eMC website or equivalent
Schedule for follow-up l Table updated to include patients who are administered second-
line treatment after RSI/seizure stop time
l Column included to confirm consent process for each patient
14-day follow-up questionnaire l 14-day follow-up questionnaire to be provided to both
participants who have consented on site and at home
l Follow-up for participants who have not completed their 14-day
follow-up questionnaire. Research nurse to complete the
follow-up via telephone
Blood samples l Location of blood sample: ‘Capillary/cannula samples
are acceptable’
Consent study l Consent study interviews to occur until data saturation is
achieved (maximum of 25 interviews removed)
l Not-treated participants now included in the consent study
Urgent safety measures l Process for urgent safety measures added
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Protocol section Summary of changes
Protocol deviation and serious breaches l Process for protocol deviations and serious breaches
reporting added
Records retention l Maximum archiving period updated to 25 years
l Clarification when study information is sent via encrypted
e-mails
l Removal of records management service by the University of
Liverpool. Regulations to be followed when archiving quoted
N/A l Other minor typographical errors, corrections and clarifications
to ensure consistency made throughout
CTRC, Clinical Trials Research Centre; eMC, electronic medicines compendium; HTA, Health Technology Assessment;
N/A, not applicable; SmPC, Summary of Product Characteristics.
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Appendix 5 Patient and public involvement
The lead PPI contributor was a mother of a child with a severe form of epilepsy caused by a geneticdisorder. In the first 6 years of her life, her daughter had experienced frequent episodes of CSE
that had resulted in numerous attendances in the ED or hospital admissions. It was considered that she
would be a valuable member of the team and was involved throughout the development of the grant
application and included as a co-applicant.
Aims
The key aims of her involvement were to comment on the clinical relevance of the subject of the
trial and to provide input on those methodologies that related to patient-recruitment and RWPC,
including the patient and participation information leaflets and the process for obtaining consent
post discharge.
Methodology
The methodology focused on the following.
l Providing input on the terminology and practice of ‘deferred consent’ (i.e. RWPC). This included
advice on the content and structure of site training for the simulated interview of taking informed
deferred consent from families.
l A review of the parent/patient information leaflets and covering letters.
l Attendance at the TMG meetings, which were predominantly undertaken by telephone conference.
Study results
The lead PPI attended TMG meetings at which the results of the EcLiPSE trial and the nested consent
study were discussed.
Reflections
The PPI agreed that the trial was important and felt that the primary and secondary outcomes were
appropriate and relevant. She felt that she had a specific value in guiding other members of the TMG
in the potential consequences of seeking deferred consent in an emergency and emotionally sensitive
situation. This included invaluable comments in how to best communicate with the parents of a child
who had died and had been recruited into the EcLiPSE trial. She was concerned about two issues
over her involvement. First, that she was unable to participate in many of the regular TMG meetings,
primarily because of their dates and times, which clashed with her work responsibilities and childcare.
Second, because of the specialised pharmacological aspects of the trial, which at times she felt were
somewhat ‘over her head’, despite explanations provided by the chief investigator and clinical members
of the TMG.
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Report writing, academic paper preparation and dissemination
The PPI was not actively involved in the writing of the protocol (published in the online journal Trials2),
but did comment on the final draft prior to its publication. Her input was similar in the definitive results
paper (published online in The Lancet1). She also contributed to the final report to the Health Technology
Assessment programme, with her focus being on the Plain English summary and preparation of the
end-of-study results information sheet for all participating sites and their teams. She will continue to
be involved in dissemination activities and preparation of academic papers.
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Appendix 6 Primary outcome proportionality
assumption
All children
TABLE 15 Unadjusted Cox proportional hazards model (all children)
Variable HR (95% CI) p-value
Levetiracetam vs. phenytoin 1.2 (0.91 to 1.6) 0.2
TABLE 16 Unadjusted Schoenfeld residuals for primary outcome (all children)
Supremum test for proportional hazards assumption
Variable Maximum absolute value Replications Pr >MaxAbsVal
Levetiracetam vs. phenytoin 0.6100 1000 0.7200
MaxAbsVal, Maximum Absolute Values; Pr, probability.
TABLE 17 Adjusted Schoenfeld residuals for primary outcome (all children)
Supremum test for proportional hazards assumption
Variable Maximum absolute value Replications Pr >MaxAbsVal
Levetiracetam vs. phenytoin 0.6207 1000 0.7100
Sex: female vs. male 0.9470 1000 0.2520
Weight 1.8151 1000 0.0050
First seizure: no vs. yes 0.9665 1000 0.2670
MaxAbsVal, Maximum Absolute Values; Pr, probability.
DOI: 10.3310/hta24580 Health Technology Assessment 2020 Vol. 24 No. 58
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Appleton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
79
Children with a weight of < 12 kg
1.0
0.8
0.6
0.4
0.2
0.0
Su
rv
iv
al
 p
ro
b
ab
ili
ty
0 200 400 600 800
Minutes
+ Censored
Log-rank p = 0.3108
Levetiracetam
Phenytoin
52
42
16
18
16
18
16
18
0
3
Allocation
Levetiracetam
Phenytoin
FIGURE 8 Kaplan–Meier for children with a weight of < 12 kg. Product-limit survival estimates with number of subjects at risk.
TABLE 18 Unadjusted Schoenfeld residuals for children with a weight of < 12 kg
Supremum test for proportional hazards assumption
Variable Maximum absolute value Replications Pr >MaxAbsVal
Levetiracetam vs. phenytoin 0.4659 1000 0.8870
MaxAbsVal, Maximum Absolute Values; Pr, probability.
TABLE 19 Unadjusted HRs for children with a weight of < 12 kg
Variable HR (95% CI) p-value
Levetiracetam vs. phenytoin 1.301 (0.776 to 2.181) 0.3185
TABLE 20 Adjusted Schoenfeld residuals for children with a weight of < 12 kg
Supremum test for proportional hazards assumption
Variable Maximum absolute value Replications Pr >MaxAbsVal
Levetiracetam vs. phenytoin 0.4595 1000 0.9040
Sex: female vs. male 1.0542 1000 0.1410
Weight 1.2529 1000 0.1400
First seizure: no vs. yes 0.8390 1000 0.2930
MaxAbsVal, Maximum Absolute Values; Pr, probability.
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Children with a weight between 12 and 36 kg
TABLE 21 Adjusted HRs for children with a weight of < 12 kg
Variable HR (95% CI) p-value
Levetiracetam vs. phenytoin 1.250 (0.737 to 2.120) 0.4087
Sex: female vs. male 1.020 (0.599 to 1.736) 0.9418
Weight 1.172 (0.873 to 1.573) 0.2910
First seizure: no vs. yes 1.495 (0.862 to 2.593) 0.1526
1.0
0.8
0.6
0.4
0.2
0.0
Su
rv
iv
al
 p
ro
b
ab
ili
ty
0 200 400 600 800
Minutes
+ Censored
Log-rank p = 0.6760
Allocation
Levetiracetam
Phenytoin
Levetiracetam
Phenytoin
86
80
27
26
0
3
27
25
27
25
FIGURE 9 Kaplan–Meier for children with a weight between 12 and 36 kg. Product-limit survival estimates with number
of subjects at risk.
TABLE 22 Unadjusted Schoenfeld residuals for children with a weight between 12 and 36 kg
Supremum test for proportional hazards assumption
Variable Maximum absolute value Replications Pr >MaxAbsVal
Levetiracetam vs. phenytoin 0.7902 1000 0.3950
MaxAbsVal, Maximum Absolute Values; Pr, probability.
TABLE 23 Unadjusted HRs for children with a weight between 12 and 36 kg
Variable HR (95% CI) p-value
Levetiracetam vs. phenytoin 1.081 (0.748 to 1.561) 0.6791
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TABLE 24 Adjusted Schoenfeld residuals for children with a weight between 12 and 36 kg
Supremum test for proportional hazards assumption
Variable Maximum absolute value Replications Pr >MaxAbsVal
Levetiracetam vs. phenytoin 0.8037 1000 0.3870
Sex: female vs. male 0.7263 1000 0.5030
Weight 0.9563 1000 0.2280
First seizure: no vs. yes 0.7400 1000 0.5240
MaxAbsVal, Maximum Absolute Values; Pr, probability.
TABLE 25 Adjusted HRs for children with a weight between 12 and 36 kg
Variable HR (95% CI) p-value
Levetiracetam vs. phenytoin 1.080 (0.742 to 1.571) 0.6886
Sex: female vs. male 1.036 (0.710 to 1.511) 0.8540
Weight 0.998 (0.968 to 1.029) 0.9047
First seizure: no vs. yes 0.960 (0.629 to 1.465) 0.8497
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FIGURE 10 Kaplan–Meier for children with a weight of > 36 kg. Product-limit survival estimates with number of
subjects at risk.
TABLE 26 Unadjusted Schoenfeld residuals for children with a weight of > 36 kg
Supremum test for proportional hazards assumption
Variable Maximum absolute value Replications Pr >MaxAbsVal
Levetiracetam vs. phenytoin 1.0623 1000 0.0910
MaxAbsVal, Maximum Absolute Values; Pr, probability.
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TABLE 27 Unadjusted HRs for children with a weight of > 36 kg
Variable HR (95% CI) p-value
Levetiracetam vs. phenytoin 1.845 (0.712 to 4.781) 0.2072
TABLE 28 Adjusted Schoenfeld residuals for children with a weight of > 36 kg
Supremum test for proportional hazards assumption
Variable Maximum absolute value Replications Pr >MaxAbsVal
Levetiracetam vs. phenytoin 1.1107 1000 0.0860
Sex: female vs. male 0.8301 1000 0.5380
Weight 0.7626 1000 0.6220
First seizure: no vs. yes 0.8002 1000 0.2320
MaxAbsVal, Maximum Absolute Values; Pr, probability.
TABLE 29 Adjusted HRs for children with a weight of > 36 kg
Variable HR (95% CI) p-value
Levetiracetam vs. phenytoin 1.690 (0.621 to 4.599) 0.3043
Sex: female vs. male 0.934 (0.276 to 3.162) 0.9128
Weight 1.039 (0.977 to 1.104) 0.2201
First seizure: no vs. yes 2.084 (0.455 to 9.538) 0.3443
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Appendix 7 Primary outcome sensitivity
analyses
Time to seizure cessation using Gray’s test for competing risks
TABLE 30 Time to seizure cessation using Gray’s test for competing risks
Event
Group, n (%)
Levetiracetam (N= 152) Phenytoin (N= 134)
Number of events of interest (seizure cessation) 106 (69.74) 86 (64.18)
Number of competing events (RSI) 46 (30.26) 48 (35.82)
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FIGURE 11 Cumulative incidence plot.
TABLE 31 Time to seizure cessation using Gray’s test for competing risks results (unadjusted Fine and Gray model)
Variable Sub-distribution hazard ratio (95% confidence interval) p-value
Levetiracetam vs. phenytoin HR for seizure cessation 1.202 (0.908 to 1.592) 0.1976
HR for RSI 0.837 (0.560 to 1.250) 0.3843
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Time to seizure cessation from infusion
Time to seizure cessation censoring at time of second second-line treatment
TABLE 32 Time to seizure cessation from infusion
Variable
Group
Levetiracetam (N= 152) Phenytoin (N= 134)
Number of events (seizure cessation), n (%) 106 (69.74) 86 (64.18)
Number of censored times (RSI), n (%) 46 (30.26) 48 (35.82)
Median time (minutes) to cessation of seizure
from start of infusion (IQR)
17.50 (8.00–NA) 24.50 (8.00–NA)
NA, not assessable.
TABLE 33 Unadjusted Schoenfeld residuals for time to seizure cessation from infusion
Supremum test for proportional hazards assumption
Variable Maximum absolute value Replications Pr >MaxAbsVal
Levetiracetam vs. phenytoin 0.6704 1000 0.5850
MaxAbsVal, Maximum Absolute Values; Pr, probability.
TABLE 34 Time to seizure cessation from infusion results (unadjusted Cox proportional hazards model)
Variable HR (95% CI) p-value
Levetiracetam vs. phenytoin 1.153 (0.867 to 1.532) 0.3279
TABLE 35 Time to seizure cessation censoring at time of second second-line treatment
Variable
Group
Levetiracetam (N= 152) Phenytoin (N= 134)
Number of events (seizure cessation), n (%) 98 (64.47) 85 (63.43)
Number of censored times (RSI), n (%) 41 (26.97) 45 (33.58)
Number of censored times (second second-line treatment), n (%) 13 (8.55) 4 (2.99)
Median time (minutes) to cessation of censoring at time of second
second-line treatment (IQR)
35 (20–NA) 45 (24–NA)
NA, not assessable.
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TABLE 36 Unadjusted Schoenfeld residuals for time to seizure cessation censoring at time of second second-line treatment
Supremum test for proportional hazards assumption
Variable Maximum absolute value Replications Pr >MaxAbsVal
Levetiracetam vs. phenytoin 0.8734 1000 0.3200
MaxAbsVal, Maximum Absolute Values; Pr, probability.
TABLE 37 Time to seizure cessation censoring at time of second second-line treatment results (unadjusted Cox
proportional hazards model)
Variable HR (95% CI) p-value
Levetiracetam vs. phenytoin 1.152 (0.861 to 1.540) 0.3412
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Appendix 8 Example telephone interview
and focus group questions
Interview topic Example question
Practitioners
Knowledge and experience pre training Please define your role in the EcLiPSE trial
Prior to the EcLiPSE trial did you have any previous experiences of
trial recruitment? If yes, how long have you worked in trials? Have
you been in any trials that used RWPC (deferred consent)?
How many children have you personally recruited to the
EcLiPSE trial?
How many children has your site recruited to the EcLiPSE trial?
Thoughts about the EcLiPSE trial before
training and practitioner engagement with
the trial
What were your thoughts about the EcLiPSE trial before the SIV?
Prompt: did you have any concerns?
What was the feeling among your site colleagues about the EcLiPSE
trial before the meeting?
Do you think there was support for the trial? Prompt: was there
‘buy-in’ for this study before the meeting?
What do you think helps with getting ‘buy-in’ from the site team?
Experience and of training Is there anything that stands out about the training? Prompt:
anything you found particularly useful/anything not useful?
What did you think about the randomisation video? Prompts: how
useful was it? Anything you did not find useful? Did you watch it
again after the training?
What did you think about the consent video? Prompts: how useful
was it? Anything you did not find useful? Did you watch it again
after the training?
Did you have a simulation? Prompts: how useful was it? How could
it have been improved?
Consent in emergency care When you first heard that the EcLiPSE trial was to use a RWPC
(deferred consent) approach, what were your initial thoughts?
Did you have any concerns? If yes, what were they?
Have your views about deferred consent changed over time? If yes,
could you tell me a bit more about that? At what point did they
change before/after SIV? After experience of RWPC?
Consent process: randomisation Who is responsible for doing what?
How do you think the randomisation process has been going so far?
Do you open the envelope in front of parents? If no, why?
Do you have posters/leaflets up on the wall in resus? Have any
parents asked about the EcLiPSe trial in resus? What questions
have parents asked in resus? Have there been any awkward parent/
doctor conversations? Has a parent declined to participate in resus,
what happened? Have you ever given any brief information about
the trial during resus or soon afterwards? (Explore)
Is the randomisation/resuscitation process smooth? Do you think it
could be improved? (Discuss)
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Interview topic Example question
Parents
Consent process Would you mind if I start by getting an overall picture of what
happened when you first heard about the EcLiPSE trial . . . could you
tell me a bit about that? (Explore any knowledge about the trial
before admission)
During the actual treatment in the room where your child was
having the seizure, did you ask any questions about the study?
What were you told?
Did you see any leaflets or posters about the trial?
Could you tell me what they explained about the EcLiPSE trial?
Could you tell me what the EcLiPSE trial was looking at?
What do you think about the use of deferred consent in an
emergency situation (e.g. when a child has entered hospital via
accident and emergency or born very early)?
Decision-making Did you feel that your child may benefit from taking part in
the trial?
Could you describe the possible benefits you expected your child to
gain from taking part in the EcLiPSE trial?
Did this influence your decision in any way?
Assent Did the nurse or doctor explain the EcLiPSE trial to your child and
give them a leaflet to seek their permission to take part? If yes:
l Could you tell me a bit more about that?
l Do you think they understood the information they were given?
l Did they give their permission to take part?
l Did they ask any questions?
Improving the trial and research discussion in
the future
When do you think is the best time to approach parents to obtain
consent in an emergency situation?
When do you think parents should be consulted about their child’s
involvement in an emergency trial? Prompt: what if the trial
involved a new drug? Could you tell me a bit more about your
reasons for this?
Is deferred consent acceptable for that type of research?
Who do you think should approach the parents about a trial?
Prompt: do you think it should be a doctor or nurse involved in a
child’s care who approaches parents about a trial? Do you think it
should be someone separate from the care team? Could you tell me
why you think this?
Resus, resuscitation area.
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Appendix 9 Consent study participant
characteristics
Characteristics: parents
All parents who took part in the consent study had consented to the use of their child’s information in the
EcLiPSE trial. Despite attempts to involve decliners, none of the 19 parents who declined the use of their
child’s data in the EcLiPSE trial consented to participate in the consent study. None of the parents included
in the nested consent study lost a child, although fortunately very few children involved in the EcLiPSE trial
died. No individuals identified themselves as legal representatives and therefore this term is not used in
the remainder of this appendix.
Of the 143 parents who returned a questionnaire, 93 (65%) were mothers and 39 (27%) were fathers.
Ten (7%) had missing parent information.
One parent was present in approximately half (41/76, 54%) of the recorded trial discussions, whereas two
parents (or family members) were present in 35 (46%) discussions. Details of who (e.g. mother, father or
relative) took part in recorded trial discussions could not be fully established, as not all individuals recorded
completed the consent form. Of the 76 recorded trial discussions, 37 (49%) children had received phenytoin
and 35 (46%) children had received levetiracetam. In four discussions it was unclear which study drug the
child had received. Recorded trial discussion data suggested that 31 out of 76 (40%) children in this
subsample had experienced previous seizures, whereas 17 (22%) had not. In 28 (36%) children it was not clear
whether or not the child had experienced a previous seizure. In total, 21 out of the 76 (21%) parents indicated
that their child had previously taken, or was currently taking, levetiracetam as a preventative treatment.
LR interviewed 30 parents (i.e. 25 mothers and five fathers) over the telephone at a mean of 6 weeks
(range 1–8 weeks) after their child had been discharged from hospital. Interviews ranged from 18 to
63 minutes (mean 34 minutes). Eighteen parents reported that their child had experienced previous
seizures prior to their child’s involvement in the EcLiPSE trial. For 12 parents, this was their child’s first
seizure. Children of parents involved in the consent study were aged between 9 months and 8.5 years
at the time of recruitment to the EcLiPSE trial (with a median of 2.8 years) compared with a range of
6 months to 17 years 11 months (with a median of 2.8 years) for the EcLiPSE trial sample (379 children).
Thirteen parents reported their child being randomised to levetiracetam and 10 parents said that their
child was randomised to phenytoin. In six cases, the parent reported that they could not remember
what trial drug was given and one knew both had been given, but was unsure of the order in which
they were given.
Characteristics: practitioners
As shown in Figure 12, SIV questionnaire respondents comprised 45 (36%) nurses and 57 (46%) doctors.
Those who defined themselves as ‘other’ had specific roles (e.g. ‘nurse specialist hospice’). Six nurses
and four doctors took part in a telephone interview. All had a lead role (e.g. principal investigator, lead
research nurse) in the EcLiPSE trial recruitment. Telephone interviews lasted, on average, 37 (range
21–47) minutes. Of the 36 practitioners who took part in one of the six focus groups, 20 (56%) were
nurses and 16 (44%) were doctors. On average, focus groups lasted 61 (range 37–88) minutes. Of the 199
practitioners who took part in the online questionnaire, 39% (n = 78) were nurses, 59% (n = 117) were
doctors and 5% (n = 3) were classified as ‘other’ (e.g. clinical research lead). It is likely that some of the
practitioners who took part in a telephone interview, focus group or SIV questionnaire also completed
the online questionnaire.
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EcLiPSE consenting practitioners attended SIV
training at 26 sites involved in the evaluation
(n = 312)
Received RWPC training and were
eligible for inclusion, n = 149/312 (48%)
Excluded owing to missing data, n = 24/149 (16%)
Questionnaires
(n = 125/149, 84%)
Nurses, n = 45 (36%)
Doctors, n = 57 (46%)
Other, n = 23 (18%)
Took part in SIV training, n = 125 (100%)
Interviews
(n = 10)
Nurses, n = 6 (60%)
Doctors, n = 4 (40%)
Other, n = 0 (0%)
Took part in SIV training, n = 10 (100%)
Six focus groups
(n = 36)
Nurses, n = 20 (56%)
Doctors, n = 16 (44%)
Other, n = 0 (0%)
Took part in SIV training, n = 18 (50%)
Online questionnaire
(n = 199)
Nurses, n = 78 (39%)
Doctors, n = 117 (59%)
Other, n = 3 (5%)
Took part in SIV training, n = 124 (62%)
FIGURE 12 Practitioner characteristics by method.
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TABLE 38 Practitioner confidence in aspects of consent-seeking by experience of RWPC before and after training
I feel confident
in . . .
Before training, n (%) After training, n (%) Changes in confidence after training, n (%)
Strongly
disagree
Mildly
disagree
Neither
agree nor
disagree
(neutral)
Mildly
agree
Strongly
agree
Mean
confidence
score
Strongly
disagree
Mildly
disagree
Neither
agree nor
disagree
(neutral)
Mildly
agree
Strongly
agree
Mean
confidence
score Improved Decreased
No
change
Mean difference
(95% CI) p-value
1. Explaining the study
to families
11 (9) 27 (22) 30 (24) 30 (24) 27 (22) 3.28 0 (0) 0 (0) 4 (3) 52 (42) 69 (55) 4.52 82 (66) 4 (3) 39 (31) –1.24 (–1.46 to –1.02) 0.000
a
2. Explaining
randomisation to
families
8 (6) 7 (6) 20 (16) 49 (39) 41 (33) 3.86 0 (0) 0 (0) 2 (2) 42 (34) 81 (65) 4.63 58 (47) 3 (2) 64 (51) –0.77 (–0.96 to –0.57) 0.002
b
3. Explaining RWPC to
families
c
20 (16) 24 (19) 40 (32) 21 (17) 20 (16) 2.98 0 (0) 1 (1) 12 (10) 48 (39) 61 (50) 4.39 90 (72) 2 (2) 32 (26) –1.40 (–1.62 to –1.17) 0.000
a
4. Dealing with parents
who object to their
child being randomised
8 (6) 28 (22) 29 (23) 30 (24) 30 (24) 3.37 0 (0) 2 (2) 16 (13) 56 (45) 51 (41) 4.25 64 (51) 5 (4) 56 (45) –0.88 (–1.08 to –0.68) 0.000
b
a Paired samples t-test.
b Wilcoxon sign-ranks test.
c Missing responses: n= 3 (2%) (after training).
Notes
Totals may not equal 100% because of rounding.
D
O
I:
1
0
.3
3
1
0
/h
ta2
4
5
8
0
H
ealth
T
ech
n
o
lo
gy
A
ssessm
en
t
2
0
2
0
V
o
l.2
4
N
o
.5
8
©
Q
u
een
’s
P
rin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
2
0
.T
h
is
w
o
rk
w
as
pro
d
u
ced
b
y
A
ppleto
n
et
al.u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cial
C
are.T
h
is
issu
e
m
ay
b
e
freely
repro
d
u
ced
fo
r
th
e
pu
rpo
ses
o
f
private
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,th
e
fu
ll
repo
rt)
m
ay
b
e
in
clu
d
ed
in
pro
fessio
n
al
jo
u
rn
als
pro
vid
ed
th
at
su
itab
le
ackn
o
w
led
gem
en
t
is
m
ad
e
an
d
th
e
repro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g.
A
pplicatio
n
s
fo
r
co
m
m
ercial
repro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
al
In
stitu
te
fo
r
H
ealth
R
esearch
,
E
valu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lph
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
pto
n
Scien
ce
P
ark,So
u
th
am
pto
n
SO
1
6
7
N
S,U
K
.
9
3
TABLE 39 Staff views on trial conduct and training dissemination 8 months before
anticipated end of trial recruitment (n = 199)
Statement n (%)
The trial is running well and we have no issues 125 (63)
The trial is running well but we do have some issues 40 (20)
The trial is not running well as we have some issues 5 (3)
Staff shortages have led to patients being missed 13 (7)
There is a lack of support from the central EcLiPSE trial team 1 (1)
Site training is not frequent enough 11 (6)
It is difficult to find staff to cover consent-seeking 5 (3)
There is a lack of support for the EcLiPSE trial at site 2 (1)
Anxieties about research without consent are a barrier to recruitment 2 (1)
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Appendix 10 How trial information about
the trial was exchanged during discussion
about recruitment to the EcLiPSE trial
Respond to patients’ concerns 
Show confidence and a relaxed manner 
Explain
illness
Reasure
about
receiving
treatment
Establish
uncertainty
Explain trial
aims
Give a
balanced
description
of
treatment
strategies
Explain trial
procedures
FIGURE 13 A six-step model for recruitment to a RCT (from Realpe et al.57).
Explain
the
condition
Discuss
trial
purpose
Explain
RWPC 
Establish
uncertainty
Give
balanced
decription
of the trial
treatments
Provide a clear
explanation of
randomisation
Check
understanding
Respond to parents’ questions and concerns 
Show confidence and a relaxed manner
FIGURE 14 A seven-step framework to assist recruitment in trials that involve RWPC.
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